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1.1. CYSTIC FIBROSIS
Cystic Fibrosis (CF) is the most common life-shortening genetic disorder in the white 
population.1 It affects approximately 1300 individuals in the Netherlands2 and 60.000 
individuals worldwide. CF is caused by mutations in the cystic fi brosis transmembrane 
conductance regulator (CFTR) gene, which is expressed in many organ systems, including 
the respiratory and gastro-intestinal tracts. Over 1600 mutations of the CFTR gene have 
been described. The prevalent mutation leading to CF is the deletion of phenylalanine 
at codon 508 (phe508del, until recently known as ∆F508). This is found in about 70% of 
the patients. Different mutations in the CFTR gene have varying effects on CFTR function 
and can result in different phenotypes of the disease. The CFTR protein primarily func-
tions as an ion channel that regulates liquid volume on epithelial surfaces through chlo-
ride secretion and inhibition of sodium absorption. Impaired or absent CFTR function 
leads to a reduced volume of airway surface liquid in the lungs, which negatively affects 
the mucociliary clearance (MCC). This in turn leads to chronic and severe lung disease 
that starts in infancy. Treatment of CF is lifelong, complex and intensive. Fortunately, the 
predicted survival of CF patients has steadily improved over the last decades. The me-
dian age of survival in the United States reached 36.9 years in 2006.3 This progress is due 
to much better nutritional management, the provision of care through multidisciplinary 
specialized CF centres, and more effective antibiotics and mucolytic agents.4 
1.1.2. CF lung disease
CF lung disease is known to develop in the fi rst several months of life in most chil-
dren. The airways of infants who died with CF in the fi rst days of life appeared to be 
normal with no evidence of infection, infl ammation, or signifi cant mucus plugging.4,5 
The typical features of CF lung disease include mucus plugging of the airways, hyper-
trophy and hyperplasia of the secretory elements, and chronic infection, primarily with 
Staphylococcus aureus and Pseudomonas aeruginosa.5 Retention of mucus is thought 
to favour bacterial overgrowth, which then triggers a cycle of repeated or chronic infec-
tions associated with intense neutrophilic airway infl ammation. Chronic infection and 
infl ammation result in airway wall thickening and plugging of bronchioles with purulent 
secretions, a process that is thought to begin in the peripheral airways.4 
At some point in the disease process, cough becomes a prominent symptom in most 
patients. Patients with early disease may cough during exacerbations only, but with pro-
gression of  CF lung disease cough becomes chronic. Cough in CF is usually associated 
with expectoration of sputum. For most patients daily sputum volume increases with 
age. Blood-streaked sputum and hemoptysis occur more frequently in more advanced 
disease. Similar to chronic obstructive pulmonary disease, CF patients experience dys-
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pnea on exertion and shortness of breath as the lung disease progresses. In end stage 
lung disease patients often become oxygen dependent (at least at night) with retention 
of carbon dioxide. In addition they experience progressive worsening of their quality 
of life (QoL) and exercise tolerance as they have more exacerbations and respiratory 
therapy is intensifying.1
In end stage lung disease most patients have little normal functional lung parenchyma 
left.6 Most of the lung volume is occupied by bronchiectasis and/or air trapping. It is 
worth noting that the onset of these structural abnormalities is in infancy. Bronchiecta-
sis (Figure 1a) is known to be an irreversible pulmonary condition. There is increasing 
awareness that air trapping (Figure 1b) starts early as well in the disease process and 
that it is an important component of respiratory failure in end stage lung disease in 
most patients.7,6 Respiratory failure still is the major cause of death among patients with 
CF.
1.1.3. CF Gastrointestinal disease
In addition to the CF lung disease most patients usually present with signs and symp-
toms of gastrointestinal disease as well. Around 10% of the CF patients present in the 
neonatal period with meconium ileus. Furthermore, cholestatic jaundice can be ob-
served. Pancreatic insuffi ciency is present in 85% of the CF patients at the time of di-
agnosis. Infants with CF and pancreatic insuffi ciency may show a low body mass index, 
defi ciencies of fat-soluble vitamins and failure to thrive. Hepatosplenomegaly and liver 
cirrhosis can develop later in life and were found to occur in 2% to 37% of all patients. 8,9 
Improved survival has led to a growing number of patients with CF-related diabetes, i.e. 
A)  B)
Figure 1. 
a) Inspiratory computed tomography scan of CF patient with severe bronchiectasis (see arrows). 
b)  Expiratory computed tomography scan showing hypodense areas indicating trapped air adjacent to areas of more 
normal density. Note the contrast between hyper and hypodense areas (see arrows).
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1around 16% of adolescents and adults. CF-related diabetes could result in more severe 
disease.10
1.1.4. Management of CF patients
The management of CF patients takes place primarily in specialized CF centres. Most 
centres have different teams for children and for adult patients. A CF team typically 
includes (pediatric) pulmonologists, (pediatric) gastroenterologists, dieticians, physio-
therapists, CF nurses, psychologists, microbiologists, pharmacists, and geneticists. The 
aim of the CF teams is to provide state of the art management of CF patients, as docu-
mented in guidelines and protocols. A key element of the treatment of CF is that the 
patients are seen frequently, and have easy access to the team in case of problems. In 
addition to patient care, CF centres participate in clinical and/or basic research on dif-
ferent aspects of CF. Some CF centres will manage some of their patients in assisted care 
with a general hospital, which can deliver part of the care close to home. 
1.1.5. Treatment of CF lung disease
The primary aim of therapy in CF lung disease is to preserve the normal architecture of 
the lung and to prevent any damage from occurring. Therapy includes frequent treat-
ment with antibiotics, mucoactive drugs and airway clearance techniques (ACT). Ag-
gressive preventive treatment is important because most structural lung damage is irre-
versible. Treatment is demanding for the patient and parents and is lifelong. Adherence 
to therapy from infancy into adulthood is the major challenge of the CF team and the 
patient alike.4,11 
1.2. MUCOCILIAIRY CLEARANCE 
Normal lungs are kept clean and free from infection in part through the process of 
mucociliary clearance (MCC). Thus, debris and bacteria present in inhaled air become 
embedded in the mucus on the surface of the airways. This mucus is continuously trans-
ported by the cilia on the airway surface out of the lung toward the pharyngeal cavity 
from where it is swallowed. While the tips of the cilia project into the mucus during their 
forward propulsive stroke, the greater part of each cilium is bathed by a less viscous 
fl uid, the periciliary liquid (PCL) that lines the airway surface.12
For normal MCC it is necessary that the airway epithelial cells are intact, cilia structure 
and activity are normal, depth and chemical composition of the PCL are optimal, and 
the rheology of mucus is within the physiological range.13 
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In CF the CFTR dysfunction leads to depletion of the PCL resulting in compressed cilia, 
which can decrease both mucociliary and cough clearance. 5,14 The defi cient MCC con-
tributes to the infection by preventing effective clearance of bacteria out of the respira-
tory tract. 5 In addition, there is an excessive infl ammatory response to pathogens, which 
mechanism is poorly understood.7 
In patients with CF more DNA is present in the sputum.15 This DNA is released by dis-
integrated infl ammatory cells, particularly neutrophils.16,17 Higher DNA content in CF 
mucus is associated with higher mucus viscosity.18 
As part of the infl ammatory response neutrophils are releasing large quantities of pro-
teases, such as elastase, which contribute to structural airway damage.19 This damage 
further impairs MCC and facilitates the attachment and growth of bacteria, thus rein-
forcing the vicious circle.4
The impaired MCC is an important characteristic of CF that is present early in life and 
worsens with increasing disease severity.20,21,13,22 (Figure 2)
Impaired MCC causes mucus to accumulate in the airways. Accumulation of mucus 
contributes to airfl ow obstruction. This obstruction increases the work of breathing, 
produces ventilation-perfusion mismatch, and can result in impaired gas exchange. Re-
tained mucus can further facilitate bacterial growth and thus can worsen infl ammation.23 
For CF patients with compromised MCC cough is an important mechanism to clear the 
entrapped mucus from the airways.13 Cough clearance becomes more important when 
mucus-cilia interaction is compromised.24 However, cough by itself is relatively inef-
1RUPDO &\VWLF)LEURVLV
Figure 2. Schematic of ciliated airway epithelial cells expressing normal (left) and mutant (right) 
CFTR. The normal cel has fully extended and functional cilia and the epithelial cell with mutant 
CFTR has compressed cilia with increased mucus, decreased epithelial lining fl uid and essentially no 
mucociliary clearance.
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1fi cient in CF patients to clear the thick, impacted mucus. For this reason a variety of 
ACT such as forced expiration techniques, PEP mask, autogenice drainage, fl utter, and 
active cycle of breathing techniques have been developed to facilitate MCC.  Besides 
ACT, CF patients use mucoactive drugs, which aim to change the properties of airway 
secretions.25 
1.2.1. Airway clearance techniques 
ACT are considered the cornerstone in the treatment of CF. Approximately 90% of the 
CF patients use some form of ACT.26,27
The goal of ACT in CF is to improve the removal of mucus from the airways. It has been 
shown that cough and forced expiration techniques, which are elements of ACT, are ef-
fective in clearing secretions from the inner and intermediate lung regions.28 Effective 
ACT can improve ventilation-perfusion mismatch, reduce airway resistance, and de-
crease proteolytic activity in the airway.29 In general ACT aims fi rstly to increase expira-
tory fl ows in partially obstructed airways and thus to mobilize the sputum. Secondly to 
increase the lung volume above tidal volume level, which reduces collateral ventilatory 
resistance and allows air to fl ow behind secretions aiding their mobilization. 
There has been a substantial change in ACT over the last decade.30 From more passive 
techniques – for example clapping – physiotherapists are now instructing more active 
techniques to their patients – like active cycle breathing techniques, autogenic drain-
age, PEP mask (Figure 3), fl utter, and huffi ng. 
Exercise is increasingly regarded as an essential part of the overall physiotherapy man-
agement of CF. Exercise increases the respiratory minute volume and recruits lung 
zones. As a result high fl ows occur in the central airways, boosting the MCC.29,31  Exercise 
in addition improves general fi tness, patient’s self-esteem, and measures of QoL. Exer-
cise is socially acceptable and helps to normalize the patient’s life rather than adding a 
therapy that accentuates differences from peers.32
A meta-analysis has shown that the combination of ACT with exercise is associated with 
a statistically signifi cant increase in lung function over ACT alone.33 However, in adults 
with CF, ACT resulted in a higher production of sputum than exercise alone.34 Hence, 
exercise is considered an important add-on strategy to improve MCC, but it cannot 
replace ACT. 
In general ACT are not well standardized. Major differences between centres can be 
observed in frequency, timing, duration, and intensity. Selection of the best ACT for a 
patient is determined by many factors such as therapy adherence, use of concomitant 
medications, and character of the patient. All these factors make it diffi cult to design 
and conduct rigorous clinical trials to improve our understanding of the various ACT. 
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Importantly, for ethical reasons it is not possible to conduct double-blind studies in CF 
patients comparing a specifi c ACT to no ACT.29
Several short- to medium-term studies support the use of ACT in CF. In the Cochrane 
review ‘Chest physiotherapy compared to no chest physiotherapy for CF’ it is concluded 
that ACT have short-term effects in terms of increasing mucus transport. However, no 
conclusive evidence is available on the long-term effects of ACT.35 
1.2.2. Mucoactive drugs
Recombinant human deoxyribonuclease (rhDNase) was one of the fi rst drugs specially 
developed for CF that was shown to be effective.36 RhDNase is delivered once daily by 
nebuliser as an aerosol.37 RhDNase, which is an enzyme, cleaves extra cellular DNA, 
which is present in high concentrations in purulent CF sputum.
Daily treatment with rhDNase reduces the number of pulmonary exacerbations, im-
proves pulmonary function and QoL, and is well tolerated and safe in patients with mild, 
moderate and severe CF.38-44 
1.1.3. RhDNase and ACT
The effectiveness of ACT can be impaired when the mucus is thick and dehydrated.45 
For this reason most patients combine ACT with the use of mucoactive drugs. Though 
the effectiveness of rhDNase, a mucoactive drug, is well established, very little research 
has been carried out to determine the time relation between rhDNase nebulisation and 
ACT. The sequence in which rhDNase and ACT should be used is not known. About 50% 
of the patients use rhDNase before ACT – and 50% use it after. 26,46 Furthermore, there is 
Figure 3. Child with a PEP mask.
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1no agreement on the optimal timing of rhDNase nebulisation during the day. The Epi-
demiologic Registry of Cystic Fibrosis showed that 51.3% of the patients used rhDNase 
in the morning, 37.4 % in the evening, 8.1% varied between morning and evening, and 
usage was not specifi ed in 3.2%.26 
RhDNase is an enzyme with a half-life in rodents of at least 11 hours after inhalation. 47 It 
requires time to act upon the mucus. In test tube conditions all the sputum moved freely 
down the tube after 30 minutes.37 The duration of the half-life in humans is not known. 
Based on these in-vitro data patients are often advised to use the rhDNase minimally 
30 minutes before ACT. Still there are reasons to believe that it may be advantageous to 
nebulise rhDNase after ACT. As a result of ACT the mucus will be mobilised and airway 
patency will improve. This is likely to result in a more peripheral and homogenous de-
position pattern of nebulised rhDNase.22,48
Another treatment option that has been suggested, is to nebulise rhDNase before go-
ing to sleep and to do ACT in the morning. Firstly, it would allow suffi cient time for rhD-
Nase to act upon the free DNA present in the airway lumen. Secondly, changes in pos-
ture during sleep might act like postural drainage therapy; allowing gravity dependent 
mobilization of the sputum. During sleep adults have an average of 16 position shifts 
per night.49 These more or less random changes might be helpful to clear the liquefi ed 
mucus from the airway. Postural drainage during sleep is therefore likely to improve 
MCC. However, a number of theoretical arguments against the nebulisation of rhDNase 
before sleep have been suggested. Firstly, MCC was depressed during sleep in normal 
subjects 50 and in subjects with asthma 51. In addition, it was shown that dehydrated se-
cretions are capable of triggering coughing spells during sleep in CF.52 Secondly, nightly 
spontaneous cough might be less effective to expectorate sputum relative to daytime 
cough. As a result the liquefi ed sputum instead of being expectorated could even wors-
en peripheral airway obstruction. Thirdly, when nebulisation before the night should 
result in increased cough during the night, sleep quality could be reduced.52 However, 
the assumptions as discussed above were never systematically studied. 
1.3. OUTCOME MEASURES FOR CF LUNG DISEASE 
To measure the effect of therapy – in clinical management and clinical studies – sensi-
tive and clinically relevant endpoints are needed. True endpoints are mortality and slope 
of decline in lung function. With median survival of almost 40 years, mortality is no 
longer a feasible outcome parameter in CF. Similarly, slope of decline in lung function is 
not a feasible outcome parameter due to the variability of the measurement and due to 
the slow annual rate of decline. 
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Hence, surrogate endpoints must be used to monitor the effect of therapy in clinical 
management and clinical studies. Surrogate endpoints are outcome measures that fi rst 
must have reasonable high reproducibility (precision) and must be accurate predictors 
of primary endpoints. Finally a change in score within an individual must correspond 
to a change in risk in the right direction for the primary endpoint of interest within that 
individual; the validity requirement. 53,54,55
Standardized equipment and techniques should be available with which to feasibly per-
form the measurement. In addition it is important that the result of the measurement 
can be expressed numerically. Ideally, the endpoint would also be measured with mini-
mal risk and be inexpensive and easy to perform.54
Surrogate endpoints that are used in CF include: function parameters; pulmonary ex-
acerbation rates; QoL measures; growth; sputum cultures; infl ammatory markers; na-
sal potential difference; chest radiograph scores and chest computed tomography (CT) 
scores (Table 1).54 
Lung function parameters such as the Forced Expiratory Volume in one second (FEV1) 
traditionally have been used as the primary endpoint in many therapeutic studies in 
CF. Ironically, the improvements in lung function among patients with CF over the past 
decade have rendered these measurements less useful as clinical trial endpoints, since 
the annual rate of decline has become very small and its variability remained high.54 
Furthermore, there is interest in endpoints which can reduce the sample size require-
ments for CF studies.55 Hence, there is great need for new sensitive and precise surro-
gate endpoints.56
1.3.1. Outcome measures in ACT studies
Standardized outcome measures for ACT are not well developed. There are several 
problems with ACT studies in CF. First, there is no gold standard by which to compare 
new outcome measures. Secondly, due to the use of a wide variety of outcome measures 
studies are diffi cult to compare and results are often confl icting. And thirdly, most ACT 
studies are too small and statistically underpowered to provide conclusive evidence.57 
In three Cochrane reviews about ACT techniques a total of 34 studies were reviewed. 
In total 809 patients, aged 0-41 years, participated in these studies. In these studies 37 
different outcome measures were used.35,58,59 The most commonly used (>10%) outcome 
measures were pulmonary function parameters, sputum weight, oxygen saturation, and 
radiolabelled imaging. 
Exercise and admissions were used in three out of the 34 studies (9%). (Figure 4) Vital 
capacity, peak fl ow, functional residual volume, RV/TLC, growth, patient preference, in-
travenous antibiotics administration were used in two (6%) studies. Quality of life, use 
of antibiotics, gastro-oesophageal refl ux, body mass index, days in hospital, symptom 
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score, cough score and counting, gas mixing, and other pulmonary lung function tests 
– for example expiratory rest volume and airway resistance – were used in one study 
(3%) only. Note that quality of life is used in one study only. A missing but interesting 
outcome is costs. 
In the next section we will discuss the advantages and disadvantages of a number of 
relevant outcome parameters that can be used in ACT studies. In Table 2 these advan-
tages and disadvantages, as well as the questions to be answered in the future, are 
summarized.
1.3.1.1. Pulmonary function test
The most widely used pulmonary function test is spirometry. From spirometry vari-
ous parameters can be obtained. FEV1 is widely used to evaluate ACT effectiveness.
60 
It is questionable whether FEV1 is a valid endpoint in ACT studies in CF. For one, the 
measurement of FEV1 refl ects airway patency of especially the central airways. FEV1 is 
considered insensitive to detect localized structural damage. In addition it is insensitive 
to events in the peripheral airways.61 Furthermore it is unclear whether FEV1 is able to 
detect changes in mucus transport.60,61  During ACT patients can mobilize mucus from 
the peripheral airways into the more central airways, which action may reduce FEV1. 
Hence, FEV1 seems to be of little value to evaluate the effectiveness of ACT. An interest-
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Figure 4. Frequency of most used outcome measures used in 34 studies of Airway Clearance 
Techniques in Cystic Fibrosis. (Based on 35,58,59)
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1ing alternative parameter that can be obtained from spirometry is the MEF25 or FEF75
1. 
This fl ow parameter is considered a sensitive indicator of the condition of the peripheral 
airways.. In addition it is abnormal in an early stage of the disease and has been shown 
to be responsive to therapy.41,61
1. MEF25 or FEF75: both terms are used in this thesis
Table 2. Examples of surrogate endpoints that can be used in ACT studies in CF.
Endpoint Age (yr) Standardized Disadvantages Advantages Questions 
Spirometry >6 yes -  No standardized 
defi nition
-  FEV1 not sensitive in 
early lung disease
- Not invasive
-  Clinically 
relevant 
-  Responsiveness to ACT 
interventions 
Airway 
resistance
All ages Yes - All ages
- Not invasive
-  Clinically 
relevant 
-  Responsiveness to ACT 
interventions 
-  Correlation with other 
outcome measures
Oxygen 
saturation
All ages No - All ages
- Not invasive
-  Clinically 
relevant 
-  Responsiveness to ACT 
interventions 
- Reproducible
-  Correlation with other 
outcome measures
Radioactive 
tracers
? Yes -  Unethical in children 
because of radiation 
exposure
- Expensive
- All ages
-  Clinically 
relevant 
Sputum 
collection
>6
No
-  Many patients not able 
to expectorate sputum
- Not precise
- Not invasive
-  Clinically 
relevant 
-  Correlation with other 
outcome measures
Exercise 
testing
>4 Several used 
tests
-  Insensitive to early 
disease
- No immediate effect
- Not invasive
-  Clinically 
relevant 
-  Responsiveness to ACT 
interventions 
Quality of 
Life
> 6 Yes (CFQ) - Not invasive
-  Clinically 
relevant 
-  Validated 
instrument
-  Responsiveness to ACT 
interventions 
Cough All ages More scoring 
systems 
available
-  Measuring cough during 
the day is diffi cult
-  Scoring is time 
consuming
- All ages
- Not invasive
-  Clinically 
relevant 
-  Responsiveness to ACT 
interventions 
- Reproducible
-  Correlation with other 
outcome measures
ACT= airway clearance techniques, CFQ = Cystic Fibrosis Questionnaire
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1.3.1.2. Airway resistance
Several techniques are available to measure airway resistance. It has been shown that 
ACT has a positive effect on specifi c airway resistance as measured by plethysmography 
62, suggesting a positive effect of ACT on central airway clearance.63,64 An alternative and 
easier tool to measure respiratory system resistance may be the interrupter technique 
or Rint (Figure 5).65 
Rint is sensitive to changes in central airway calibre in children with mild respiratory 
tract infections, it can be performed quickly in the ambulatory setting, and it has been 
shown to be reproducible.66,67 Rint measurement is therefore a promising outcome mea-
sure to detect changes in the central airways.  
1.3.1.3. Oxygen saturation
The primary function of the lung is gas exchange, i.e. the uptake of oxygen from the air 
and elimination of carbon dioxide. In CF patients gas exchange can be impaired due to 
airway obstruction. This can result in hypoxemia and hypercapnia.68-72 Nocturnal oxygen 
desaturation and reduced resting daytime oxygen saturation have been described in CF 
patients.52 Oxygen saturation can be measured by pulse oximetry, which is a non-inva-
sive, reliable and simple method for children of all ages.73 It can be measured relatively 
easy with a fi nger probe. (Figure 6)
Reference values of overnight oxygen saturation are well established for healthy chil-
dren.74-80 Surprisingly few studies in children with stable CF have been performed using 
oxygen saturation.78,81,82 In one it was shown that structural lung abnormalities on CT 
correlated with mean nocturnal oxygen saturation.82 It is not known if oxygen saturation 
is sensitive to ACT treatment changes in children with CF. 
Figure 5. Rint measurement.
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Clearly, oxygen saturation needs further exploration before it can be used as an out-
come measure in ACT studies. 
1.3.1.4. Radioactive tracers 
Measurement of mucus transport by means of radioactive tracers is an attractive method 
for short term studies in CF.13,22,60 The use of radioactive tracers in clinical practice is 
technically demanding, however, and raises some ethical concerns as far as children are 
concerned. Therefore, this method is not a feasible outcome parameter in larger scale 
clinical studies. 
1.3.1.5. Sputum collection
In many studies sputum weight and/or volume have served as outcome parameters 
because these are relatively easy measured. Yet this method has some major drawbacks. 
Patients often are reluctant or not able to expectorate sputum effectively. Then there is 
the risk of inadvertent swallowing of secretions and of contamination of the secretions 
by saliva.60 Furthermore, in younger children it is mostly not possible to obtain reliable 
sputum samples. As a result sputum weight and/or volume is not a feasible endpoint.
1.3.1.6. Exercise testing
Exercise capacity is an important parameter in children with CF and it correlates with a 
child’s functional capacities.83 A high level of aerobic fi tness in patients with CF is associ-
ated with a lesser risk of dying.84
Figure 6. Probe attached to a patient’s fi nger to measure oxygen saturation.
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Exercise testing is underutilized in studies, which is unfortunate, since it is probably a 
better predictor of long-term survival than are lung function parameters. One of the 
problems in performing exercise testing is that many CF centres do not have the spe-
cialized laboratory testing equipment or manpower necessary to assess aerobic/anaer-
obic fi tness. For these reasons, fi eld exercise tests such as the shuttle test, or 6-minute 
walk test, have been introduced. Although they have been validated, there are still little 
data on reference values and on criteria by which value changes are to be considered 
clinically signifi cant.29
Exercise testing is probably only useful as an outcome measure in long term ACT studies 
exploring whether functional capacities will improve by an ACT treatment change. 
1.3.1.7. Quality of life
Health related QoL as an outcome measure in clinical trials is becoming increasingly im-
portant. Registration of new drugs not only requires to demonstrate the pharmacologic 
activity, but also to demonstrate its effect on QoL. QoL measurement provides a way of 
incorporating the child’s and parent’s perspective on how CF and its therapies impact 
on their physical, social and psychological functioning.85,86 A CF-specifi c health-related 
measure, the Cystic Fibrosis Questionnaire (CFQ), has been developed and validated 
in many countries, such as the Netherlands.85,87-89 The CFQ takes developmental stages 
into account and makes it possible to monitor the health status from the age of 6 years 
throughout adulthood. 
The CFQ has been used in only few ACT studies.60 The CFQ is still a relatively new instru-
ment and many questions still have to be answered before it can be used on a wider 
scale. Most importantly, the minimal relevant changes in the various domains have not 
been well defi ned. Furthermore, it has not been well validated against other endpoints 
such as bronchiectasis. Recently, a new inhaled antibiotic was approved for CF based 
on a study in which the respiratory domain of the CFQ was one of the secondary end-
points.90 This illustrates that the CFQ is becoming an important instrument in CF. Clearly 
it is highly relevant to include the CFQ in future ACT studies. It seems that the ‘treat-
ment constraint’ item from the quality of life domain and the respiratory part from the 
symptom scale are the most relevant elements for use in ACT studies. 
1.3.1.8. Cough
Cough is one of the defensive refl exes of the respiratory tract 91 and  it is part of the 
mucociliary escalator.13 Cough accompanied by expectoration of sputum is a prominent 
daily symptom in CF patients.4 Increased cough is an important symptom of a pulmo-
nary exacerbation.92,93 This is why cough is included in most defi nitions of a pulmonary 
exacerbation and can potentially serve as an objective surrogate parameter for an exac-
erbation.93 Surprisingly, cough is rarely used in ACT studies. 
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1Severity of cough in clinical studies has been assessed using a visual analogue scale 
or the cough symptom score.94,95 These subjective cough scores correlate only mod-
erately well to more objective measurements such as time spent coughing.96 Clearly, a 
more objective method to record cough is important. Currently available cough meters, 
which consist of electromyogram electrodes and a microphone, are expensive, and data 
analysis is time consuming and requires a trained investigator.94,97,98 The manual count-
ing of cough sounds from digital audio recordings is a more patient friendly alternative 
method that has shown excellent agreement with cough as recorded on video.99 
Cough in daily life is best measured during sleep. Cough registrations during sleep have 
been examined in adult patients with CF.52,72 To our knowledge this method has not yet 
been applied in children with stable CF. Since cough is an important component of an 
exacerbation, objective cough measurement in children with CF needs to be further 
studied.  
1.4. ADHERENCE TO ACT
CF treatment is demanding, time consuming and lifelong. Most CF patients require daily 
intensive treatment at home that can consist of nebulisation of mucolytics and antibiot-
ics, as well as oral antibiotics, pancreatic enzymes, vitamin or nutritional supplements. 
Furthermore, daily ACT is essential, and so is a healthy lifestyle with adequate nutri-
tion and exercise. Treatment becomes more intensive during disease exacerbations and 
with progression of the disease. New drugs are currently being developed and some of 
those will be added to the already impressive daily treatment package. It is not to be 
wondered at, therefore, that lifelong adherence to this burdensome therapy is a major 
challenge for the patients, parents and the CF team.100 Poor adherence to therapy often 
brings worsening of the disease 100 and is considered an important prognostic factor for 
progression of the disease.101 Up to 50% of pediatric populations have been found non-
adherent to part of their CF treatment regimens.102,103 Adherence rates for ACT in chil-
dren range from 40 to 75% 103-105 and for nebulisation with rhDNase from 57 to 90%.104,106 
Adherence is a complex issue affected by variables such as: age, knowledge, economical 
status, psychosocial factors and cognitive functioning.100,107,108 
Patient knowledge of the disease and treatment regimen as well as understanding of 
the background of the physicians’ recommendations are thought to be critical to ad-
herence. Substantial gaps in knowledge about CF lung disease have been identifi ed in 
children and their parents.109 In two studies the level of adherence among children with 
CF was positively associated with the level of their knowledge of the disease.110,111 
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It would seem important, therefore, to improve in children with CF the knowledge about 
CF lung disease – with the aim to improve adherence. Unfortunately only a few tools are 
available to help educate the children in a systematic way.
1.5. SUMMARY OF THE INTRODUCTION
Cystic Fibrosis (CF) lung disease is characterized by the depletion of airway surface liq-
uid and abnormal mucociliary transport. Retention of mucus is thought to favour bacte-
rial overgrowth, which then triggers a cycle of repeated or chronic infections associated 
with intense neutrophilic airway infl ammation. This process causes progressive struc-
tural lung damage. Eventually, this leads in most patients to a reduced life expectancy
The primary aim of therapy in CF lung disease is to preserve the normal architecture 
of the lung and to prevent any damage from occurring. The cornerstone of therapy is 
treatment with effective antibiotics, mucoactive drugs, and ACT. Little is known on the 
optimal time relation between rhDNase, a mucoactive drug, and ACT. 
Assessment of (new) therapies requires reliable and validated endpoints. More sensitive 
and accurate endpoints are urgently needed to monitor CF lung disease. There is no 
gold standard to measure effi cacy in ACT studies and currently used outcome measures 
have several drawbacks. Therefore new outcome measures for ACT studies have to be 
developed and validated.
CF treatment is demanding, time consuming and life long. The high burden of CF therapy 
makes that adherence to this therapy is a major challenge for the patients, parents and 
the CF team. Adherence is affected by variables such as: age, knowledge and socioeco-
nomic factors. To increase patients’ knowledge about their disease, education should be 
an important component in CF therapy. 
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2.1. TIMING RHDNASE AND AIRWAY CLEARANCE THERAPY
The chapters 3 and 4 describe the studies that are focussed on the timing of rhDNase 
nebulisation in relation to ACT. 
In chapter 3 we describe a study in 25 children with stable CF lung disease that inves-
tigates whether inhalation of rhDNase after ACT increases peripheral airway patency 
more than in the case of inhalation of rhDNase before ACT. 
In chapter 4 we describe a study in another group of 25 children with stable CF lung 
disease. In this study we compare the effi cacy and possible side effects of nebulisation 
of rhDNase before sleep to those of nebulisation after waking up. Effi cacy was evaluated 
with pulmonary function tests. Side effects were monitored using nocturnal oxygen 
saturation and cough registration. 
2.2. OUTCOME MEASURES IN CF LUNG DISEASE
Chapters 5-7 describe studies aimed at developing outcome measures that can be used 
in ACT studies. 
In chapter 5 we investigate cough frequency during two nights in children with clinically 
stable CF, and examine cough correlation between the two nights with an one week 
interval and between the cough frequency and oxygen saturation, pulmonary function 
and CT scores. 
In chapter 6 we assess, during two nights, nocturnal saturation profi les in children with 
clinically stable CF and relate the saturation variables to lung function, cough frequency 
and structural lung abnormalities as established from CT scan. 
In chapter 7 we perform a study to assess whether Rint is a feasible outcome measure 
for ACT studies. 
2.3. PATIENT EDUCATION ON CF LUNG DISEASE
In chapter 8 we describe a study to test a newly developed educational board game – 
‘Airway’ – aimed at increasing children’s knowledge about their CF lung disease. The 
level of knowledge was tested with a knowledge questionnaire.
Chapter 9 contains a summary of the research presented in this thesis. Chapter 10 con-
tains the general discussion with recommendations for future research. 
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ABSTRACT
Introduction
Little is known about the optimal timing of rhDNase nebulization in relation to airway 
clearance therapy (ACT). Objective: To compare the effects of rhDNase before ACT ver-
sus rhDNase after ACT in children with CF. 
Methods
Design: randomized, double blind, double dummy, cross over study. Inclusion criteria: 
CF, stable clinical condition, rhDNase maintenance therapy. Children in Group I inhaled 
rhDNase 30 minutes before ACT, and placebo directly after ACT in week 1–3. The proto-
col was reversed during week 4–6. Group II performed the reversed sequence. Patients 
continued their daily routine ACT. Primary endpoint: MEF25 %pred. Pulmonary function 
tests were performed on days 0, 14, 21, 35 and 42. In weeks 3 and 6 children scored 
cough and sputum production on daily diary cards.
Results
24 patients completed the study. Mean age 12 years (range 7–19). Mean MEF25 %pred 
was 5.8% higher after 3 weeks of rhDNase before ACT, compared to rhDNase after ACT 
(58.3% vs 52.5%, p=0.01). There were no signifi cant differences for any of the other 
variables. 
Conclusion
Inhalation of rhDNase before ACT improves peripheral airway patency in children with 
cystic fi brosis. Since all children were already on maintenance rhDNase therapy before 
the study, this effect is additional to any existing effect of regular rhDNase. 
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INTRODUCTION
Cystic fi brosis (CF) lung disease is characterized by the depletion of airway surface liq-
uid and abnormal mucociliary transport. Retention of mucus is thought to favor bacte-
rial overgrowth, which then triggers a cycle of repeated or chronic infections associated 
with intense neutrophilic airway infl ammation.1 This process causes progressive struc-
tural lung damage.2 Eventually, most patients will then suffer premature death caused 
by respiratory failure.
Airway clearance therapy (ACT) and nebulisation of recombinant human deoxyribo-
nuclease (rhDNase) are known to aid sputum evacuation. Approximately 90% of CF 
patients use some kind of ACT.3 ACT effectively increases sputum mobilization, but the 
long-term effi cacy in terms of outcome compared with unassisted cough alone is un-
known.4 CF sputum is abnormally hydrated, has increased tenacity5 and contains large 
amounts of DNA.6 The DNA is released by disintegrated microorganisms and disin-
tegrated infl ammatory cells, particularlyneutrophils.7 High content of DNA correlates 
with an increased mucus viscosity.8 The effectiveness of ACT in CF is counteracted by 
abnormally thick dehydrated sputum.9 RhDNase cleaves extra cellular DNA and reduces 
sputum viscosity.10 Daily treatment with rhDNase reduces the number of pulmonary 
exacerbations, improves pulmonary function, and is well-tolerated and safe in patients 
with mild, moderate, and severe CF.11–15
Little is known, however, on optimal timing of rhDNase nebulisation in relation to ACT. A 
survey of 54 CF centers revealed that half of the patients use rhDNase before, and half after 
ACT.16 The Epidemiologic Registry of CF17 showed that 51% of the patients used rhDNase 
in the morning, 37% in the evening; and 8% at variable moments; not specifi ed in 3%.
Patients are generally advised to nebulise rhDNase minimally 30 min before ACT, be-
cause rhDNase increases the sputum pourability in a time dependent fashion; at 30 min 
the sputum is liquefi ed.10 It may be advantageous, however, to nebulise rhDNase after 
ACT. ACT induced sputum mobilization is likely to improve large airway patency and 
this would improve rhDNase deposition in the small airways. Recently a double blind 
randomized placebo controlled cross over study was conducted in CF patients who were 
not on maintenance therapy with rhDNase. FEV1 %pred after 2 weeks of rhDNase ther-
apy did not signifi cantly differ in between the use of rhDNase before or after ACT. Only 
for patients colonized persistently with pseudomonas rhDNase FEV1 %pred improved 
when rhDNase was used after ACT.18
The aim of our study was to assess the difference in effi cacy between nebulisation of 
rhDNase before ACT versus nebulisation after ACT in CF patients on maintenance therapy 
with rhDNase. We hypothesized that inhalation of rhDNase after ACT would increase pe-
ripheral airway patency, as refl ected by the maximal expiratory fl ow at 25% of the forced 
vital capacity (FVC) (MEF25 %pred), more than inhalation of rhDNase 30 min before ACT.
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MATERIALS AND METHODS
Study Subjects
Patients of the CF center at Erasmus Medical Centre-Sophia Children’s Hospital were in-
cluded in the study when they fulfi lled the following criteria: proven CF, at least 5 years 
of age, ability to perform reproducible spirometry, daily ACT treatment, on maintenance 
treatment with rhDNase and clinical stability. The latter was defi ned as no need for in-
travenous antibiotics and no hospitalizations for at least 1 month prior to the study. CF 
was defi ned as clinical symptoms characteristic of CF plus an abnormal sweat test and/
or by the presence of two CF mutations. We excluded children who used rhDNase more 
than once a day, those who were considered to have a poor adherence (<50% of treat-
ments) to nebuliser treatment as judged by the CF team, or those who were mentally 
retarded. Throughout the study, subjects continued to receive their standard treatment.
Study Design
The study had a randomized, double blind, double dummy, cross over design. All sub-
jects nebulized both rhDNase (2.5 mg of rhDNase in 2.5 ml buffered solution: 8.77 mg/ml 
sodium chloride and 0.15 mg/ml calcium chloride)19 and a placebo (2.5 ml of a buffered 
solution: 8.77 mg/ml sodium chloride and 0.15 mg/ml calcium chloride) once daily for a 
period of 6 weeks. Placebo was similar to rhDNase in both color and taste. Subjects were 
randomized in two groups. In the fi rst three weeks group I used rhDNase 30 min before 
ACT and placebo directly after ACT. In the following 3 weeks the order in which rhDNase 
and placebo were taken was reversed (Fig. 1). Group II used placebo 30 min before ACT 
and rhDNase after ACT in the fi rst three weeks, and the reverse sequence thereafter. 
Weeks 1 and 2 and Weeks 4 and 5 were considered as wash-in and wash-out periods 
based on several studies.12,14,20–22 Because patients were on maintenance treatment with 
rhDNase a true wash-out period without rhDNase was considered unethical and unprac-
tical. Patients were asked not to change their routine ACT technique. Time of the day dur-
ing which nebulisation and ACT were applied, was kept constant throughout the study. 
Placebo and rhDNase were administered using a Sidestream nebuliser (Respironics, 
Murrysville, PA) and one of the following compressors: Portaneb, Freeway Lite,- Free-
dom or CR60 (Respironics, Murrysville, PA). 
The Erasmus MC Medical Ethical Review Board approved the protocol. The study was 
performed according to ICH-GCP guidelines.
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Equipment Specifi cations
Pulmonary function tests (PFT) were carried out using a handheld spirometer (Mi-
croLoop, Micro Medical Ltd., Rochester, UK). The following PFT results were obtained: 
forced expiratory volume in 1 sec (FEV1 %pred); FVC %pred; mean forced expiratory fl ow 
between 25 and 75% of the FVC (FEF25–75 %pred) and MEF25 %pred. The PFT results were 
expressed as a percentage of predicted values.23 Interrupter resistance (Rint) (kPa/L/sec) 
was measured using the MicroRint (Micro Medical Ltd.). Calibrations of fl ow were carried 
out using a 1 L precision pump.
Procedures
PFTs were carried out at the hospital or at the patient’s home. Weight and height were 
measured on Day 0. Rint and spirometry were performed on Days 0, 14, 21, 35, and 42. 
Rint was always measured fi rst. Throughout the study, measurements were taken ap-
proximately at the same time of day and with the same equipment. Before lung function 
measurements children were asked to clear their throat by coughing. For Rint measure-
ments, children were instructed to sit upright although breathing quietly. The head was 
positioned in slight extension. The hands of the investigator supported the patient’s 
cheeks and chin to reduce upper airway compliance.24 One Rint measurement was dem-
onstrated by the investigator before the actual measurements, so as to familiarize chil-
dren with the sound of the shutter. A minimum of fi ve correct tracings (maximal 10) was 
obtained, that is, a Rint recording was accepted for further analysis if breathing had 
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Figure 1. Study design and time points for primary and secondary endpoint measurements for 
children in group I. In group II the order of the rhDNase and the placebo was reversed.
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been regular and if the mouth pressure–time curve was consistent of shape.25 The ex-
piratory Rint (Rinte) was measured, because expiratory interruptions are more sensitive 
in detecting airway obstruction relative to inspiratory interruptions.26 Spirometry was 
performed in triplicate according to ERS guidelines.27 
Patients continued their medication, such as Tobramycin solution for inhalation (TOBI) 
and inhaled steroids, throughout the study period. None were using other mucolytics 
or hypertonic saline during the study. 
Patients were asked to keep empty drug vials for vial count. The children were asked to 
keep a diary during the 3rd and 6th week. Cough frequency during day and nighttime 
were recorded with the cough symptom score (CSS) (Table 1).28 Sputum viscosity, sputum 
production and cough frequency were recorded on a visual analogue scale (VAS).28 A VAS 
is a horizontal line, 100 mm in length, anchored by word descriptors at each end. The pa-
tients marked on the line the point that represented their perception of symptom severity.
Data Analysis
Statistical analysis was performed with SPSS version 10.0. 
According to the protocol the primary outcome variable was MEF25 %pred at the end 
of each treatment period. Secondary variables were FVC %pred, FEV1 %pred, FEF25–75 
%pred, Rinte, and diary scores. 
Outcome variables were compared using the paired t-test after ensuring that there were 
no signifi cant carry-over or period effects. Mean diary data for the 3rd and 6th week 
were analyzed. 
Table 1. Cough Symptom Score
Daytime
0 no cough
1 cough for one or two short periods
2 cough for more than two short periods
3 frequent cough not interfering with normal activities
4 frequent cough interfering with school or other activities
5 distressing cough most of the day
Night time
0 no cough
1 cough on waking only/ cough on going to sleep only
2 awoken once or woken early due to coughing
3 frequent waking due to coughing
4 frequent coughs most of the night
5 distressing cough
Lianne BW.indd   42 10-07-09   11:13
rhDNase before airway clearance therapy 43
C
h
ap
te
r 
3
In order to obtain a near-normal distribution it was necessary to logarithmically trans-
form the following variables: Rinte, VAS viscosity, VAS sputum amount, and VAS night 
time coughing. For these latter variables median scores are presented.
With the number of 25 patients the power of the primary outcome variable (MEF25 
%pred) would be greater than 80% for an effect-size (difference of means/standard 
deviation) of 0.8 at an alpha (two-sided) of 5%.
RESULTS
Twenty-fi ve patients were enrolled in the study, 12 in group I and 13 in group II. One 
patient from group I developed a pulmonary exacerbation in the 2nd week and was 
excluded from the analysis. The mean adherence to study treatment, as calculated from 
the vial count, was 98 (range 83–100%). Characteristics of the study population, type of 
ACT and type of nebulisers are summarized in Tables 2 and 3. The groups did not dif-
fer for age, sex, and lung function at baseline (Table 2). No carry-over or period effect 
was observed for any of the endpoints. After 3 weeks 16 patients had a higher MEF25 
%pred when they nebulized rhDNase before ACT, for one patient it made no difference 
and in seven patients MEF25 %pred had decreased. Overall there was a signifi cant posi-
tive effect; MEF25 %pred was signifi cantly higher after 3 weeks of nebulising rhDNase 
Table 2. Characteristics of the study population (numbers of patients or mean with SD) at baseline 
for group 1 and 2. In the fi rst three weeks group I used rhDNase 30 minutes before ACT and 
placebo directly after ACT. In the following three weeks the order in which rhDNase and placebo 
were taken was reversed. Group II used placebo 30 minutes before ACT and rhDNase after ACT in 
the fi rst three weeks, and the reverse sequence thereafter. 
Group 1 Group 2
N 11 13 NS
Sex (male/female) 6 / 5 7 / 6 NS
Age (year) 11 (3) 12 (4) NS
FVC (% predicted) 93 (14) 93 (11) NS
FEV1 (% predicted) 88 (16) 88 (11) NS
MEF25 (% predicted) 56 (27) 57 (25) NS
FEF25-75% (% predicted) 73 (34) 66 (18) NS
Rinte (kPa/L/s 0.6 (0.34) 0.6 (0.22) NS
Use of TOBI (n) 7 6 NS
Use of steroids (n) 3 6 NS
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before ACT, compared to nebulising after ACT (58.3% vs. 52.5% predicted, P=0.01) (Fig. 
2). There were no signifi cant differences in any other endpoints (Tables 4 and 5). Twenty 
one percent of the patients performed nebulisation and ACT in
the morning, 21% in the afternoon, and 58% in the evening. The time of the day nebu-
lisation and ACT were performed did neither correlate with the MEF25 %pred nor with 
the cough scores. 
Table 3. ACT treatment and nebuliser use before and during the study. 
ACT (n / %)
PEP mask 18 / 75%
Flutter 3 / 13% 
Active cycle of breathing therapy 1 / 4%
Autogenic Drainage 1 / 4%
Combination 1 / 4%
Nebuliser (n / %)
Portaneb 17 / 71%
Freeway Lite 3 / 12.5%
Freeway Freedom 3 / 12.5%
CR 60 1 / 4%
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Figure 2. MEF
25
% pred according to nebulisation of rhDNase after and before ACT after 3 weeks. 
Lines connect individual data points. Bars represent mean values.
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DISCUSSION
This randomized, double blind, double dummy, cross over study aimed at assessing 
the difference in effi cacy between nebulisation of rhDNase before ACT versus nebuli-
sation after ACT. We found that the primary endpoint MEF25 %pred after 3 weeks was 
signifi cantly higher for the before mode. Other lung function parameters did not show 
signifi cant differences.
So our results suggest improved effi cacy of rhDNase when inhaled before ACT, thus 
refuting our hypothesis that nebulisation after ACT would be more advantageous.
This hypothesis was based on the concept that ACT clean out the large airways in par-
ticular. Various studies have shown that the presence of mucus in central airways favors 
central airway deposition and reduces peripheral deposition of medical aerosols.29–31 
Hence, we expected more effi cient peripheral airway deposition when rhDNase would 
be inhaled after ACT. 
Several explanations may account for our result. First, ACT done before nebulisation 
of rhDNase might mobilize sputum in cartilaginous airways towards the more central 
airways. Larger amounts of mucus in central airways will lower the amounts of rhDNase 
Table 4. Mean or median(*) lung function (%predicted and kPa-L-1.s for Rinte)  with range after two 
and three weeks rhDNase before or after ACT. ‡= p<0.05.
FVC% FEV1% MEF25% FEF25-75% RINTe*
After 2 weeks
RhDNase after ACT 94.8 (76-131) 89.5 (68-116) 54.2 (18-104) 68.1 (36-118) 0.58 (0.24-1.38) 
RhDNase before ACT 92.5 (72-123) 87.1 (57-107) 54.1 (8-103) 67.5 (19-129) 0.55 (0.19-1.84)
p- value 0.12 0.18 0.98 0.84 0.06
After 3 weeks
RhDNase after ACT 94.1 (75-131) 88.3 (67-105) 52.5 (11-93) 66.6 (36-112) 0.50 (0.21-1.36)
RhDNase before ACT 93.3 (75-127) 89.4 (66-113) 58.3 (17-105) 71.2 (31-129) 0.61 (0.2-2.26)
p-value 0.65 0.58 0.01 ‡ 0.07 0.08
Table 5. Mean or median(*) with range diary scores after three weeks rhDNase before or after ACT. 
rhDNase before ACT rhDNase after ACT P-value(paired t-test)
VAS viscosity* 1.3 (0.2 - 8.4) 1.3 (0.2 - 8.4) 0.73
VAS sputum amount* 0.7 (0 - 5.1) 1.1 (0.1- 6.6) 0.14
VAS day time coughing 1.7 (0 – 5.3) 1.9 (1,0 - 7.4) 0.51
VAS night time coughing* 0.1 (0 - 3.4) 0.2 (0 - 5.7) 0.14
CSS day time 1.4 (0 - 3) 1.6 (0 - 3.1) 0.28
CSS night time 0.4 (0 - 2) 0.7 (0 - 2.6) 0.06
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delivered to the peripheral airways and thus reduce its effectiveness to clean out pe-
ripheral airways. Second, it has been suggested that ACT may cause partial collapse of 
the central airways, which would exert immediate negative effects on ventilatory func-
tion.32 Any reduction in the cross sectional area of central airways is likely to increase 
turbulent airfl ow and increase impaction of airway particles at these sites.33 In this case, 
nebulisation of rhDNase immediately after ACT will result in more rhDNase being de-
livered to the central and not to the peripheral airways. A third, more likely explanation 
is that displacement of liquefi ed sputum in the peripheral compartment does not occur 
effi ciently when rhDNase nebulisation is not followed by ACT. The liquefying effect of 
rhDNase reaches it maximal impact 30 min after nebulisation.10 This might therefore be 
the optimal moment to perform ACT. Therefore, our data suggest that ACT 30 min after 
rhDNase is needed to remove liquefi ed sputum from especially the peripheral com-
partment and to prevent liquefi ed sputum from obstructing more peripheral airways. 
Because CF lung disease affects small airways at an early stage, these are an impor-
tant target for treatment. In the Pulmozyme Early Intervention Study (PEIT), involving 
rhDNase-naïve patients with normal FVC, but reduced FEF25–75 %pred, improved FEF25–75 
%pred by 8%. This suggests that rhDNase improves clearance of small airways, espe-
cially in early lung disease.13 
The PEIT data favor the idea to deposit as much rhDNase as possible in the periph-
eral airways. As discussed before, nebulisation of rhDNase should preferably take place 
when central airways are cleanest. To our surprise we could not fi nd any studies that 
investigated the diurnal variation of expectorated sputum. We assume that lungs most 
likely will be cleaner in the afternoon because exercise is thought to facilitate sputum 
mobilisation. This assumption, however, should be further investigated.
As expected, we did not observe a signifi cant change in FEV1 %pred in accordance with 
a recent other rhDNase timing study.18 FEV1 and FVC are considered insensitive markers 
in early lung disease compared to MEF25 %pred.
34 The latter is more sensitive to changes 
in the peripheral compartment than are FVC and FEV1.
34 The FEF25–75 %pred showed a 
trend similar to the MEF25 %pred. These two parameters are both thought to refl ect the 
condition of the peripheral compartment. However, FEF25–75 %pred is the mean fl ow 
value exhaling from 75 to 25% of vital capacity, is thought to be less sensitive for geo-
metrical changes in the peripheral compartment than MEF25 %pred. In the PEIT study 
the treatment effect on FEV1 %pred in early lung disease was only 3% (P=0.006) and 
thus substantially smaller than the 8% (P=0.0008) observed for the FEF25–75 %pred.
13 
The 6% difference in MEF25 %pred between the two regimens in the present study was 
substantial, considering that all patients were on maintenance rhDNase therapy. Timing 
of rhDNase in the PEIT study was not standardized. We speculate the treatment effect 
in the PEIT study would have been greater when all patients would have used rhDNase 
before ACT. 
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Our results showed a treatment effect after 3 but not after 2 weeks. This is in accor-
dance with the fi ndings of the rhDNase timing study by Fitzgerald et al.,18 who studied 
52 CF patients and did not fi nd a difference in FEF25–75 %pred after 2 weeks. The total 
cross-sectional area of the small airways is several orders of magnitude greater than 
the total cross-sectional area of the large airways.35 We speculate that more time is 
needed to clean a suffi cient large number of small airways and obtain the optimum 
effect. Persistence of MEF25 %pred improvement over a longer period of time needs to 
be addressed in future studies. Though patients were randomly selected from our CF 
population, they had relatively well preserved lung function. Further studies are needed 
to determine whether our fi ndings extend to patients with moderate and severe CF lung 
disease as well. A recent study in patients who were transplanted for end stage lung 
disease showed that a large percentage of small airways are obstructed by mucus.36 This 
suggests that patients with more advanced disease might benefi t from effective strate-
gies to treat the peripheral airways. Based on our results we recommend ACT should be 
done 30 min after inhalation of rhDNase. 
In conclusion, the fi ndings from this study favor nebulisation of rhDNase before ACT in 
children with mild CF lung disease who are on maintenance treatment with rhDNase.
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ABSTRACT
The present study focused on patients with cystic fi brosis (CF), who were on mainte-
nance therapy with recombinant human deoxyribonuclease (rhDNase), with the aim of 
comparing effi cacy and possible side effects of nebulisation of rhDNase when taken 
before bedtime with effi cacy and side effects when taken after waking up. 
A randomised, double-blind, double-dummy, crossover study group was used. The in-
clusion criteria were as follows: 1) CF, 2) stable clinical condition and 3) rhDNase main-
tenance therapy. Patients in group I inhaled rhDNase before bedtime and a placebo 
after waking up in weeks 1–2. The protocol was reversed during weeks 3–4. Group II 
patients performed the reverse of this sequence. Patients continued with their daily 
routine sputum expectoration. The primary endpoint was classifi ed as the maximal in-
stantaneous forced fl ow when 25% of the forced vital capacity remained to be exhaled 
(MEF25%). Pulmonary functions
 tests were performed on days 0, 7, 14, 21 and 28. At 1, 2, 
3 and 4 weeks arterial oxygen saturation and cough frequency were measured during 
the night. 
A total of 24 patients completed the study. The mean (range) age of the patients was 13 
(6–19) yrs. MEF25%, taken
 to be the primary endpoint, did not show a signifi cant differ-
ence between nebulisation of rhDNase before bedtime compared with when taken after 
waking up. Nocturnal cough, oxygen saturation, and other secondary endpoints were 
not signifi cantly different between the two study periods. 
In conclusion, the present study found that it is equally effective and safe to nebulise re-
combinant human deoxyribonuclease before bedtime compared with when performed 
after waking up in children with cystic fi brosis, who are on maintenance treatment with 
recombinant human deoxyribonuclease. 
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INTRODUCTION
Cystic fi brosis (CF) lung disease is characterised by excess mucus production and impaired 
mucociliary clearance.1 This causes the airways to become chronically infected with micro-
organisms, leading to chronic airway infl ammation and progressive structural lung dam-
age.2 CF sputum contains large amounts of extracellular DNA released by disintegrated 
infl ammatory cells, particularly neutrophils.3,4 Patients need daily treatment to reduce the 
amount of mucus in the airways, though they tend to feel this is a great burden.5 Airway 
clearance therapy (ACT) and nebulisation of recombinant human deoxyribonuclease (rhD-
Nase) are the most frequently used methods to mobilise sputum. The rhDNase cleaves 
extracellular DNA and reduces sputum viscosity, transforming it from a nonfl owing vis-
cous gel into a fl owing liquid.6 Daily treatment with rhDNase reduces the number of pul-
monary exacerbations, improves pulmonary function, is tolerated well and is safe in mild, 
moderate and severe CF cases.7-11 Although the effectiveness of rhDNase nebulisation is 
well established, little is known regarding optimal timing. The Epidemiologic Registry of 
Cystic Fibrosis reported that 51% of patients use rhDNase in the morning, 37% use it in 
the evening and 8% use it at variable times; timing was not specifi ed for 3%.12 
Theoretically, it could be effective and time effi cient for patients to nebulise rhDNase 
before bedtime. It would allow suffi cient time during sleep for rhDNase to act upon 
the free DNA present in the airway lumen. Its half-life in rodents was found to be 11 h 
after inhalation.13 Secondly, postural shifts during sleep might act like postural drainage 
therapy; allowing gravity-dependent mobilisation of the sputum. Adults were found to 
have an average of 16 position shifts per night .14 Postural drainage is reported to be 
effective when relatively large quantities of mucus of low adhesion are present in the air-
ways.15 Following nebulisation of rhDNase the mucus will become less viscous. Postural 
drainage during sleep is therefore likely to improve mucociliary clearance. 
Alternatively, there are several theoretical arguments against the nebulisation of 
rhDNase before bedtime. There are indications that mucociliairy clearance is depressed 
during sleep in normal subjects16 and in subjects with asthma17. However, in CF patients, 
the dehydrated secretions are capable of triggering coughing spells during sleep.18 Sec-
ondly, nightly spontaneous cough might be less effective to expectorate the sputum 
relative to daytime cough or active ACT. Hence, bedtime nebulisation of rhDNase might 
be detrimental to lung function. Thirdly, nebulisation-induced cough increased during 
sleep might affect sleep quality.18 Finally, nebulisation of rhDNase before bedtime might 
induce ventilation/perfusion mismatch due to additional occlusion of peripheral airways 
by the more liquid mucus. However, this has never been systematically studied. 
The current authors conducted a study in children with CF on maintenance therapy 
with rhDNase, comparing the effi cacy and possible side effects of nebulisation before 
bedtime with those of nebulisation after waking up. Effi cacy was evaluated using pul-
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monary function tests. Side effects were monitored using nocturnal oxygen saturation 
and cough frequency. The present authors hypothesised that nebulisation of rhDNase 
before bedtime would be safe and more effective in improving peripheral airway fl ow 
when compared with nebulisation after waking up. 
MATERIAL AND METHODS
Study subjects
Children attending the CF centre in the Erasmus MC, Sophia Children’s Hospital (Rotter-
dam, the Netherlands) were considered eligible for inclusion in the present study when 
they fulfi lled the following criteria: 1) proven CF; 2) minimum age of 5 yrs; 3) the ability to 
perform reproducible spirometry, forced vital capacity (FVC) >40%; 4) daily ACT, 5) main-
tenance treatment with rhDNase; and 6) clinical stability. The latter was defi ned as no need 
for intravenous antibiotics and no hospitalisations for a minimum of 1 month prior to the 
study. CF was defi ned as clinical symptoms characteristic for CF plus an abnormal sweat 
test and/or the presence of two CF mutations. The current authors excluded children who 
used rhDNase more than once a day and were considered to have poor therapy compli-
ance (<50% of treatments) as judged by the CF team; or those with learning diffi culties. 
A total of 152 CF patients were identifi ed. Of these, 49 patients did not meet the study 
inclusion criteria. Most patients were excluded on the basis that they were too young 
to perform spirometry. From the remaining 103 patients, 43 were randomly selected 
and invited to participate. Throughout the study, subjects continued to receive their 
standard treatment. 
Study design
The study had a randomised, double-blind, double-dummy, crossover design. All 
subjects nebulised both rhDNase (2.5 mg of rhDNase in 2.5 mL buffered solution: 
8.77 mg•mL–1 NaCl and 0.15 mg•mL–1 CaCl)19 and a placebo (2.5 mL of a buffered so-
lution: 8.77 mg•mL–1 NaCl and 0.15 mg•mL–1 CaCl) for a period of 4 weeks. Placebo 
was similar to rhDNase in both colour and taste. Subjects were randomised into one 
of two groups. Group I used rhDNase before bedtime and placebo in the morning di-
rectly after waking up in the fi rst 2 weeks. This order was reversed in the following two 
weeks (fi g. 1). Group II used placebo before bedtime and rhDNase after waking up in the 
2 weeks and in the reverse sequence thereafter. 
Based on previous studies, weeks 1 and 3 were considered wash-in and wash-out pe-
riods.10,20,21 As patients were on maintenance treatment with rhDNase, a true wash-out 
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period without rhDNase was considered unethical and unpractical. Patients continued 
to perform routine ACT during the study period. ACT in the morning was performed 
30 min after nebulisation. 
Placebo and rhDNase were administered using a Sidestream nebuliser (Respironics, 
Murrysville, PA, USA) and one of the following compressors: Portaneb, Freeway Lite, 
Freeway Freedom or CR60 (all Respironics). 
The present authors selected the maximal instantaneous forced fl ow when 25% of the 
FVC remained to be exhaled (MEF25%) as
 the primary endpoint, as it is more sensitive to 
changes in the peripheral compartment in early lung disease compared with FVC and 
forced expiratory volume in one second (FEV1).
22 
The study was conducted between September 2005 and June 2006. The Erasmus MC 
Medical Ethical Review Board approved the protocol. The study was performed accord-
ing to the International Conference on Harmonisation and World Health Organization 
Good Clinical Practice standards guidelines. 23
Equipment specifi cations
Pulmonary function tests (PFTs) were carried out using a handheld spirometer (Mi-
croLoop; Micro Medical Ltd, Rochester, UK). The following PFT results were obtained: 
FEV1, FVC and MEF25%. The
 PFT results were expressed as a percentage of predicted val-
ues.24 Interrupter resistance (Rint, kPa•L–1•s–1) was measured using the MicroRint (Micro 
Medical Ltd). Calibrations of fl ow were carried out using a 1–L precision pump. 
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Figure 1. Study design and time points for the primary and secondary endpoint measurements 
for children in group I. In group II the order of the recombinant human deoxyribonuclease 
(rhDNase) and the placebo were reversed. PFT: pulmonary function test.
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Procedures
PFTs were carried out at the patient’s home. Weight and height were measured on day 0. 
Rint measurements and spirometry were performed on days 0, 7, 14, 21 and 28, Rint was 
always measured fi rst. Throughout the study, the lung function measurements were per-
formed using the same spirometer in the afternoon and on the same day of the week for 
each patient. Before PFTs were performed the children were asked to clear their throat 
by coughing. For Rint measurements the children were instructed to sit upright while 
breathing quietly. The head was positioned in slight extension. The hands of the inves-
tigator supported the patient’s cheeks and chin to reduce upper airway compliance.25 A 
test measurement was done before the actual measurements to familiarise children with 
the sound of the shutter. A minimum of fi ve correct tracings (maximal 10) were obtained. 
The expiratory Rint(Rinte) was
 measured, because expiratory interruptions are more sen-
sitive in detecting airway obstruction relative to inspiratory interruptions.26 Spirometry 
was performed in triplicate according to European Respiratory Society guidelines.27 
For those patients who used tobramycin solution for inhalation (TSI) the study took 
place during the 4-week TSI-free interval. To estimate adherence to the study medica-
tion, patients were asked to keep empty drug vials for vial count. 
Arterial oxygen saturation was determined by pulse oximetry (Mars Pulse oximeter; Res-
pironics) during nights 7, 14, 21, and 28. To measure the nocturnal oxygen saturation 
profi le, a pulse oximeter sensor was attached to either the subject’s fi nger or toe during 
sleep. Data were stored on the pulse oxymeter. From this recording, the mean oxygen 
saturation was calculated. 
Cough recordings were made on a digital audio player/recorder (ArchosTM Gmini 120; Ar-
chos, Shenzhen, China) during nights 7, 14, 21 and 28, and then transferred to a computer. 
The recordings were analysed using free Open Source audio record and edit software, 
which provided a graphical display for audio analysis applications (Audacity, Boston, USA). 
A cough episode was identifi ed by having at least one explosive cough present. The 
duration of each cough episode was counted in seconds (cough seconds (cs)). If sev-
eral cough sounds occurred successively the duration of the total episode was counted. 
Cough per hour (cs•h–1) was then calculated by summing the total cs and dividing by the 
total recording time. This measure therefore encompasses an estimate of the length of 
peals of coughs.28 Counting of cough sounds from digital audio recordings has excellent 
agreement with simultaneous video recordings.29 
During weeks 2 and 4 the children recorded in a diary their day and night-time cough 
frequencies with a validated cough symptom score (CSS; table 1).30 They also rated spu-
tum viscosity, sputum production, sleep quality, appetite in the morning and cough fre-
quency on a visual analogue scale (VAS).30 A VAS is a horizontal line, 10 cm in length, 
anchored by word descriptors at each end. Rating is done by placing a mark on this line 
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in the position that best represents the child’s perception. The VAS score is the distance 
in cm between no symptom (left = 0 cm) and the mark placed by the patient. 
DATA ANALYSIS
The pre-planned primary outcome variable was MEF25%. With 24
 evaluated patients, the 
power for this parameter in the comparison of the two treatment schedules would be 
>80% for an effect-size (difference of mean±SD) of 0.8 at an alpha (two-sided) of 5%. 
Secondary outcome variables were FVC % pred, FEV1 % pred,
 Rinte, oxygen saturation, 
cough frequency and diary scores. 
Outcome variables were compared using the paired t-test after ensuring that there was 
no signifi cant carry-over or period effects. The mean values of diary scores for weeks 2 
and 4 were analysed. Statistical analyses were performed and p = 0.05 (two-sided) was 
considered the limit of signifi cance in all analyses. 
RESULTS
From the 43 randomly selected children, 13 children declined to participate and fi ve did 
not respond. The study group included 25 children, randomly divided between group 
I (12) and group II (13). Final analysis was for 24 children, as one child, randomised to 
group I, withdrew in week 3 due to a common fl u. Baseline characteristics are sum-
Table 1. Cough Symptom Score
Daytime
0 no cough
1 cough for one or two short periods
2 cough for more than two short periods
3 frequent cough not interfering with normal activities
4 frequent cough interfering with school or other activities
5 distressing cough most of the day
Night time
0 no cough
1 cough on waking only/ cough on going to sleep only
2 awoken once or woken early due to coughing
3 frequent waking due to coughing
4 frequent coughs most of the night
5 distressing cough
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marised in table 2; type of ACT and nebulisers are listed in table 3. The two randomised 
groups were comparable at baseline with respect to age, sex and lung function (table 2). 
No carry-over or period effect was observed for any of the endpoints. Mean adherence 
to the study treatment, as calculated from the vial count, was 97% (range 82–100%). 
The primary endpoint, MEF25%, did not signifi cantly differ
 (p = 0.25) between after wak-
ing up (a) or before bedtime nebulisation (b): the difference (a minus b) after 2 weeks 
was 3.38 (95% confi dence interval (CI): -2.6–9.3%; fi g 2). 
None of the secondary endpoints or safety parameters signifi cantly differed between 
the two schedules (tables 4 and 5). 
Table 2. Characteristics of the study population at baseline for group I and II 
Group I Group II
N 11 13
Sex(male/female) 3 / 8 5 / 8
Age (year) 12.5 (4.5) 13.5 (3.4)
FVC (% predicted) 81 (9) 82 (22)
FEV1 (% predicted) 74 (12) 76 (27)
MEF25 (% predicted) 49 (32) 49 (34)
Rinte (kPa/L/s) 0.5 (0.21) 0.5 (0.23)
Use of TSI (n) 3 5
Data are presented as n or mean±SD. In the fi rst 2 weeks, group I nebulised recombinant human deoxyribonuclease 
(rhDNase) before bedtime and placebo in the morning, directly after waking up. In the following 2 weeks the order in 
which rhDNase and placebo were taken was reversed. Group II nebulised placebo before bedtime and rhDNase after 
waking up in the fi rst 2 weeks and performed the reverse sequence thereafter. FVC: forced vital capacity; % pred: % 
predicted; FEV1: forced vital capacity in one second; MEF25%: maximal instantaneous forced fl ow when 25% of the FVC 
remained to be exhaled; Rinte: interrupter resistance exhaled; TSI: tobramycin solution for inhalation.
Table 3. Maintenance treatment undertaken by patients during the study 
ACT (n / %)
PEP mask 15 / 62%
Flutter 3 / 13% 
Autogenic drainage 4 / 17%
Combination 2 / 8%
Nebuliser ( n / %)
Portaneb 12 / 50%
Freeway Lite 1 / 4 %
Freeway Freedom 9 / 38%
Freeway Elite 1 / 4%
CR 60 1 / 4%
Data are presented as n (%). PEP: positive expiratory pressure. Manufacturer of all nebulisers presented in table: 
Respironics, Murrysville, PA, USA.
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DISCUSSION
In the current study the authors tested the hypothesis that before-bedtime nebulisa-
tion of rhDNase would be safe and prove more effective than nebulisation after waking 
up. However, the current fi ndings do not support the last part of the hypothesis. Both 
the primary endpoint MEF25% and secondary endpoints,
 such as cough frequency and 
nocturnal oxygen saturation, did not show signifi cant improvement after 2 weeks of 
nebulising rhDNase before bedtime, compared with nebulisation after waking up. In 
addition, cough frequency and nocturnal oxygen saturation were not signifi cantly dif-
ferent between the study periods; this supports the fi rst part of the hypothesis, i.e. that 
nebulisation of rhDNase before bedtime would be safe. 
The present authors feel that several possible explanations present themselves as to why 
no improved effi cacy after nebulisation before bedtime was found. First, sputum after 
nebulisation with rhDNase might still be too viscous to allow any extra positive effect by 
gravity. Secondly, during sleep mucociliary clearance is depressed16,17 and breathing pat-
terns change, resulting in reduced minute ventilation and tidal breathing pattern31,32 as 
well as an increased airway resistance33. If gravity and mucociliary clearance fail to mobi-
lise the viscous sputum spontaneously, it can only be cleared by high expiratory fl ows.34 
However, sleep is mostly characterised by quiet tidal volume breathing, which is likely to 
contribute little or nothing to sputum transport. Thirdly, the 2-week treatment period in 
each arm may have been too short. In a recent study by van der Giessen et al.35, who com-
pared the effect of nebulisation of rhDNase before and after ACT, the primary endpoint 
MEF25% showed no
 signifi cant difference after 2 weeks, but after 3 weeks a signifi cant 
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Figure 2. Shows the maximal instantaneous forced fl ow when 25% of the forced vital capacity 
remained to be exhaled (MEF25%) as % predicted, according to nebulisation of rhDNase at night-
time and in the morning, after 2 weeks. rhDNase: recombinant human deoxyribonuclease.
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increase by 6% was observed when rhDNase was used 30 min before ACT. A longer study 
period might have resulted in a difference between the two treatment arms. The result of 
the previous study was not known when the current study started. Extension of the treat-
ment period implied exclusion of those patients treated with TSI, since TSI greatly infl u-
ences spirometry results.36 Alternatively, each treatment arm could have been scheduled 
into the TSI negative or positive treatment period. However, this approach would have 
made the total study duration for each patient longer with the risk of higher noise and 
drop-out rates. The absence of differences in nocturnal cough frequency or oxygen satu-
ration between treatment arms suggests no major differences in sputum mobilisation. 
A positive fi nding was that before-bedtime rhDNase administration did not result in 
increased cough or reduced oxygen saturation during the night in this group of patients 
with mild-to-moderate lung function abnormalities. As suggested by some physicians, 
before-bedtime rhDNase could have increased nightly cough periods due to its effect 
on the sputum. The current authors did not fi nd any increase in cs•h–1 when rhDNase 
was nebulised before bedtime. This might have been the result of the depressed cough 
refl ex during sleep.37 Such a condition could prevent the liquefi ed sputum from being 
evacuated by cough clearance. However, the present authors believe this is unlikely, 
since oxygen saturation did not differ between the two study periods. Substantial in-
Table 4. Results from patients using recombinant human deoxyribonuclease(rhDNase) before 
bedtime or in the morning after week 1 and 2.
RhDNase before bedtime RhDNase morning p- value
After 1 week
MEF25%pred 47.2 (30.0) 45.5 (29.9) 0.59
FVC %pred 83.3(18.8) 83.0 (16.8) 0.78
FEV1%pred 75.5 (21.4) 75.1 (21.6) 0.82
Rinte 0.51 (0.22) 0.55 (0.27) 0.18
Saturation% 95.5 (1.3) 95.8 (1.9) 0.61
Cough (cs/h) 2.7 (4) 3.7 (4) 0.24
After 2 weeks
MEF25%pred 43.0 (28.4) 46.4 (28.5) 0.25
FVC %pred 83.0 (18.8) 83.1(17.7) 0.97
FEV1%pred  74.2 (21.8) 75.5 (20.6) 0.38
Rinte  0.54 (0.27) 0.54 (0.23) 0.97
Saturation% 96.1 (1.6) 96.2 (1.4) 0.78
Cough (cs/h)  3.3 (5) 3.7 (8) 0.85
Data are presented as mean±SD unless otherwise stated. MEF25%: maximal instantaneous forced fl ow when 25% of the 
forced vital capacity (FVC) remains to be exhaled; % pred: % predicted; FEV1: forced expiratory volume in one second; 
Rinte: interrupter resistance exhaled; cs: cough seconds.
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crease of peripheral airway obstruction due to liquefi ed sputum would have resulted 
in more severe ventilation/perfusion mismatch and thus, in reduced oxygen saturation. 
The oxygen saturation fi nding is therefore in line with the present PFT and cough results. 
In contrast to the present authors’ expectations, the children showed a trend towards 
better sleep quality and less daytime and night-time cough (table 5) when rhDNase was 
nebulised before bedtime. Nebulisation of rhDNase before bedtime in patients with 
mild-to-moderate lung function abnormalities seems therefore to be safe. 
How do the current study’s results translate to daily treatment for CF patients? Based on 
the present fi ndings, there are no arguments against the pre-sleep rhDNase treatment. 
However, long-term studies in larger cohorts and with additional secondary endpoints, 
such as exacerbation rate, are needed to confi rm the current study’s results. 
The present authors cannot argue that their observations would have been different for 
children with severe or end-stage lung disease. This must be investigated in a separate 
controlled trial, using similar monitoring of safety endpoints. 
In conclusion, this study showed that for children with cystic fi brosis on maintenance 
treatment with recombinant human deoxyribonuclease, it is equally effective and safe to 
nebulise recombinant human deoxyribonuclease before bedtime and to perform airway 
clearance therapy in the morning as it is to nebulise recombinant human deoxyribo-
nuclease after waking up by airway clearance therapy. It is therefore up to the children 
themselves to choose the most convenient time to nebulise recombinant human deoxy-
ribonuclease. 
Table 5. Diary scores after 2 weeks use of recombinant human deoxyribonulease(rhDNase) taken 
before bedtime or after waking up
rhDNase before bedtime rhDNase morning p-value
VAS viscosity 2.1 (1.6) 2.5 (1.6) 0.22
VAS sputum amount   1.9 (1.8) 2.1 (1.6) 0.26
VAS daytime coughing 2.2 (1.6) 2.5 (1.7) 0.27
VAS nighttime coughing 1.0 (1.0) 1.3 (1.4) 0.08
CSS daytime 1.3(0.9) 1.6 (0.9) 0.07
CSS nighttime 0.8 (0.8) 1.0 (0.9) 0.27
VAS appetite 3.0 (2.7) 3.3 (2.6) 0.35
VAS sleep quality 1.1 (1.0) 1.5 (1.30) 0.08
Data are presented as mean±SD, unless otherwise stated. VAS: visual analogue scale; CSS: cough symptom score.
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ABSTRACT
Introduction
To date no studies have been published on nocturnal cough frequency in children with 
stable CF. Aim of the study was to assess nocturnal cough frequency in children with 
CF. In addition nocturnal cough frequency was correlated with parameters of disease 
severity. 
Methods
During two nights cough was recorded with a digital audio recorder in 25 patients 
(mean age 13 years; range 6-19) with clinically stable CF. In addition oxygen saturation 
was measured. The day following the recording spirometry was carried out. CT scores 
were obtained from the most recent routine CT scan. Cough was expressed in cough 
seconds (cs) and in cough seconds per hour (cs/h). 
Results
Data shown are median values and interquartile range (IQR).
First night: 8 cs (IQR 3-52); 0.9 cs/h (IQR 0.3-6.1) Second night: 6 cs (IQR 2-32); 0.6 cs/h 
(IQR 0.1-3.4). Cs in the 1st night did not correlate signifi cantly with cs in the 2nd night. 
Only for the 2nd night a strong correlation was found between cs/h and the FEV1 %pred 
(rs= -0.75, p<0.001) and FEF75 %pred (rs= -0.71, p<0.001). Bronchiectasis score correlat-
ed borderline with the mean cs/h of both nights (rs= 0.39, p=0.08). During both nights 
cough was signifi cantly higher in the fi rst hour of sleep (p≤0.04). 
Conclusion
Frequency of nocturnal coughing in children with CF was higher than that described 
for normal children. Nocturnal cough tended to be more severe in children with more 
advanced CF lung disease. Nocturnal cough was more severe in the fi rst hour of sleep 
and varied from night-to-night. 
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INTRODUCTION
Cystic Fibrosis (CF) lung disease is characterized by abnormal mucus and by impaired 
mucociliary clearance.1 This impairment can lead to pulmonary exacerbations, charac-
terized by respiratory symptoms such as increased cough, higher sputum production, 
and fatigue. Pulmonary exacerbations are used as outcome measures in many clinical 
trials, in spite of the fact that objective criteria for an exacerbation are hard to defi ne.2 
Increased cough is highly associated with a pulmonary exacerbation2 and could there-
fore be used as an objective surrogate parameter for an exacerbation. 
Severity of cough in clinical studies has been assessed using a visual analogue scale 
(VAS) or the cough symptom score (CSS).3,4 These subjective cough scores correlate only 
moderately well to more objective measurements such as time spent coughing.5 Clearly, 
a more objective method to record cough would be preferred. Currently available cough 
meters are expensive, and data analysis is time consuming and requires a trained in-
vestigator.3,6,7 The manual counting of cough sounds from digital audio recordings is 
a more patient friendly alternative method that has shown excellent agreement with 
cough as recorded on video.8 Various methods have been described to quantify cough. 
Either the number of explosive phases or the cough seconds are counted. It is thought 
that these cough parameters are interchangeable.9 Recently a new method for quantify-
ing cough in cough seconds was developed.10,11 This method can be further improved 
with the use of modern digital audio recording and by using dedicated software to 
analyse the recordings. 
Currently, the best feasible and objective way of measuring cough in daily life is during 
sleep. Nocturnal cough in healthy children is unusual and often related to upper air-
way infections.12 Asthma and asthma-like symptoms, protracted bronchitis, and upper 
airway cough syndrome were detected in order of frequency as the reason for chronic 
cough in children.13 Postnasal drip syndrome and gastro-oesophageal refl ux are in con-
trast to adults rare as a cause of isolated chronic cough in children.14
Cough during sleep has been examined before in adult patients with CF.15,16 To our 
knowledge this has not yet been studied in children with stable CF. We therefore as-
sessed cough frequency during two nights in children with clinically stable CF, and ex-
amined cough correlation between the two nights with a one week interval and be-
tween the cough frequency and oxygen saturation, pulmonary function and CT scores. 
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MATERIAL AND METHODS
Study subjects
Patients of the CF centre at Erasmus Medical Centre – Sophia Children’s Hospital were 
eligible when they fulfi lled the following criteria: proven CF, defi ned as clinical symp-
toms characteristic for CF plus an abnormal sweat test and/or by the presence of two 
CF mutations; at least fi ve years of age; ability to perform reproducible spirometry; and 
clinical stability. The latter was defi ned as: absence of symptoms of a common cold; no 
need for intravenous antibiotics; and no hospitalizations for at least one month prior to 
the study. Throughout the study, subjects continued to receive their standard treatment.
This study was a sub study of a randomized controlled cross-over trial on the effect of 
the administration of rhDNase before or after the night.17 Cough was included as a safe-
ty endpoint. One group used rhDNase before bedtime and placebo (2.5 ml of a buffered 
solution: 8.77 mg/ml sodium chloride and 0.15 mg/ml calcium chloride) in the morning 
directly after waking up in the fi rst two weeks. This order was reversed in the following 
two weeks. A second group used placebo before bedtime and rhDNase after waking up 
in the fi rst two weeks, and in reverse sequence thereafter. All subjects performed airway 
clearance therapy 30 minutes after the morning nebulisation.
For the present analysis we only used the subjects’ cough registrations for the two 
weeks when placebo was inhaled before the night and rhDNase in the morning. Nebu-
lisation of placebo is thought to have no infl uence on sputum viscosity and thus is 
unlikely to have any effect on cough.
The study was conducted between September 2005 and June 2006. The Erasmus MC 
Medical Ethical Review Board approved the protocol. The study was performed accord-
ing to ICH-GCP guidelines. 
Equipment specifi cations
Pulmonary function tests (PFT) were carried out using a handheld spirometer (Mi-
croLoop, Micro Medical Ltd, Rochester, UK). The following PFT results were obtained: 
forced expiratory volume in one second (FEV1); forced vital capacity (FVC); and FEF75. The 
PFT results were expressed as percentages of predicted values.18 
Procedures
Cough recordings
Recordings (32 bits mp3 format) were made at home during nights 7 and 14 in those 
weeks when placebo was inhaled before sleep. A digital audio player/recorder (Archos 
TM Gmini 120, Shenzhen, China) was placed on a stable surface as close as possible to 
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the patient. The recording was for obvious logistical reasons started when children were 
put to bed. 
Cough recordings were transferred from the digital recorder to a personal computer. The 
recordings were analysed using free open source audio record & edit software, which 
provided a graphical display for audio analysis applications (Audacity, Boston, USA).
The investigator (LvdG) identifi ed by ear all sounds detected by the software on the 
digital recordings. The cough counting was started when the children stopped making 
noise like talking, singing or making noisy movements and when quiet breathing could 
be heard. The beginning of a cough episode was defi ned as the moment when a clear 
explosive cough was heard. Next, duration of this cough episode following the initial 
cough was computed in seconds. Finally, from total duration of cough seconds for that 
night and total time of the recording we computed the cough seconds per hour (cs/h). 
In case multiple cough sounds occurred in quick succession, we assumed this as one 
episode, lasting from the onset of the fi rst cough sound up to and including the last of 
the quickly succeeding cough sounds.11,19 An example of cough analysis is displayed in 
Figure 1. 
Pulmonary function tests
PFT took place at the patient’s home and were performed by LvdG. Weight and height 
were measured on day 0. On the days following the nightly cough registration, spirom-
etry was performed in triplicate according to ERS guidelines.20
CT score
Severity of the structural lung changes was estimated using the Brody-II CT score.21 This 
system typically evaluates the following qualities: bronchiectasis; airway wall thickening; 
mucus plugging; and opacities on inspiratory images, and air trapping on expiratory 
images. Scores were expressed as percentages of the maximum possible score on a 
VHF VHFVHF
$ %
Figure 1. Example of cough analysis. The cough duration in example A is calculated as one cough 
second. The cough in period B is calculated as two seconds; if there were several coughs occurred 
successively, the number of seconds in which these sounds fell were counted.
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scale from 0 (no disease) to 100 (maximum lung disease). For scoring we used the CT 
scan obtained at the patient’s most recent annual routine evaluation prior to the study. 
A single experienced independent observer (ML) who was unaware of the cough regis-
trations scored all CT scans in random order. 
Oxygen saturation
Oxygen saturation was measured by pulse oximetry (Mars Pulse oximeter, Respiron-
ics, Murrysville, Pennsylvania, USA), simultaneously with the cough measurements. A 
Y-sensorTM measuring the oxygen saturation was positioned at a fi nger or a toe. Mean 
oxygen saturation was computed from artifact free time.
Diary
During the second week the children were asked to keep a diary. Cough frequency dur-
ing night time was estimated with the CSS the day after the recording (Table 1).4 The 
patients themselves scored sputum viscosity, sputum production, sleep quality, appetite 
in the morning and cough frequency on a visual analogue scale (VAS).4 A VAS is a hori-
zontal line, 100 mm in length, anchored by word descriptors at each end. Scoring is by 
placing a mark on the line that best represents one’s perception of the issue. 
Data analysis
Statistical analysis was performed with SPSS version 11.0.
Cough frequency and the cs/h were expressed as median values and interquartile range 
(IQR). Spearman rank correlation coeffi cient (rs) was used to examine relations between 
cs/h of the two different nights and between cs/h and lung function, age and the CT 
score. The mean cs/h of the two study nights was used to investigate correlations with 
parameters (age and CT-score) that were similar for the fi rst and second night. For other 
parameters with more day to day variability we analyzed the correlations between cs/h 
and those parameters for each of the 2 nights separately. The relations between cs/h on 
one hand and PFT parameters and oxygen saturation on the other hand for each of the 
Table 1. Cough Symptom Score – Night time
Night time
0 no cough
1 cough on waking only/ cough on going to sleep only
2 awoken once or woken early due to coughing
3 frequent waking due to coughing
4 frequent coughs most of the night
5 distressing cough
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two study days were evaluated using repeated measures ANOVA. In this analysis cs/h 
data were logarithmically transformed to obtain approximately normal distributions. 
Values of cs/h equal 0 were replaced by 0.05 before this transformation, which only has 
a minor effect on the results.
The Wilcoxon Rank test and the Friedman test were used to compare the consecutive 
hours of sleep.
Differences were considered signifi cant at a value of p<0.05.
RESULTS
The CF-centre at the Erasmus MC-Sophia Children’s Hospital follows 152 CF-patients. 
Forty-nine of them did not meet the study inclusion criteria. Of the remaining 103, 43 
children were randomly selected and invited to participate in the study. Of these, 13 
declined to participate, and 5 did not respond. The study group therefore consisted of 
25 children. Final analysis was done on 24 children, as one child withdrew in the third 
week of the study due to a common cold. Characteristics of the study population are 
summarized in Table 2. 
The mean total recorded time from the fi rst night was 557 minutes (range 419-724) and 
from the second night 562 minutes (range 403-713). 
Cough recordings for 2 children were unsuccessful in the fi rst week, and for 3 in the 
second week. The 5 unsuccessful recordings were due to parents failing to operate the 
digital audio recorder. 
During the 1st night a median of 8 cough seconds (IQR 3-52) and 0.9 cs/h (IQR 0.3-6.1) 
were recorded and during the 2nd night a median of 6 cough seconds (IQR 2-32) and 
0.96 cs/h (IQR 0.1-3.4). During the 1st night 19 out of 22 children had one or more cough 
seconds and during the 2nd night 17 out of 21 children had one or more cough seconds. 
Table 2. Characteristics of the study population (numbers of patients or mean with range) at 
baseline
Gender (male/female) 7 / 15
Age (years) 12.8 (6.3-18.9)
FVC %pred 80 (47-114)
FEV1 %pred 72 (32-105)
FEF75 %pred 45 (6-112)
CT score 15 (0-37)
Bronchiectasis score 14 (0-47)
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Cough seconds during the 1st night did not signifi cantly correlate with the cough sec-
onds during the 2nd night (rs=0.29, p=0.20). The same applied to cs/h (rs=0.35, p=0.12). 
See Figure 2.
PFT parameters correlated very strongly between the two study days; FVC %pred 
(rs=0.95, p<0.001), FEV1 %pred (rs=0.91, p<0.001), FEF75 %pred (rs=0.94, p<0.001).
Figure 3 shows cough seconds as a function of the fi rst eight hours spent in sleep dur-
ing the second night. Cough is signifi cantly higher in the fi rst hour of sleep relative to 
all consecutive hours (all p ≤0.04) with the exception of the 7th hour of sleep during the 
fi rst night (p=0.27). There were no signifi cant differences in cough seconds between the 
other hours of sleep. 
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Figure 2. Cough seconds per hour (on a log scale) during night 1 and 2. No signifi cant relation 
between these nights were observed (r
s
 0.35, p=0.12). Individual data points are connected with 
straight lines.
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Figure 3. Cough seconds during the fi rst eight consecutive hours of sleep at night 2. Each symbol 
represents the cough seconds of one patient at that specifi c hour.
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For the 2nd night, but not for the fi rst, we found a strong correlation between cs/h and 
the FEV1 %pred (rs= -0.75, p<0.001) and FEF75 %pred (rs= -0.71, p<0.001). No signifi cant 
correlation could be found between cs/h and:  FVC %pred; or the mean oxygen satura-
tion. Further analysis evaluating both nights simultaneously using repeated measures 
ANOVA showed that the relation between FEF75 %pred versus cs/h did not signifi cantly 
differ between the two evaluated nights. There was a signifi cant common correlation 
between FEF75 %pred and cough seconds per hour. For a decrease of the FEF75 %pred 
by 10 percentage points the cs/h increases by a factor 1.4 (p=0.002; 95% CI 1.15-1.73). 
See Figure 4. 
There was a moderate correlation between the mean cs/h of the two nights and age 
(rs=0.46, p=0.04). No correlation was found between total CT score and the mean cs/h 
of the two nights. The bronchiectasis score showed borderline signifi cant correlation 
with the mean cs/h of the two nights (rs=0.39, p=0.08). The correlation for age and CT 
was rs=0.67, p=0.001, and correlation between age and bronchiectasis score rs=0.73, 
p<0.000. 
We did not fi nd correlations between cs/h and the subjective VAS score for nocturnal 
cough or sleep quality. The CSS, on the contrary, showed a moderate signifi cant correla-
tion with cs/h (rs=0.55, p= 0.01). 
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Figure 4. Scatter plot of cough sec/hour versus FEF75 %pred for the two study nights. Lines 
represent regression lines. Note the logarithmically scaled vertical axis.
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Finally, most of the children slept for at least eight hours. We therefore repeated all 
analyses just using the data for the fi rst eight hours. This resulted in similar outcomes.
DISCUSSION
To our knowledge this is the fi rst study which quantifi es the nocturnal cough frequen-
cies in children with clinically stable CF. We found that more than 80% of the children 
were coughing during the two nights that cough was recorded. This is substantially 
higher than the 5% reported in ‘normal’ children.12 Of 41 children studied, one had one 
episode of coughing and one child had three episodes of coughing. Cough was also 
studied in a cohort of children with primary ciliary dyskinesia.22 The median cough fre-
quency, defi ned as total number of cough episodes (<2 sec between individual coughs), 
was similar to that found in our study. Our study, however, showed a wider range of 
coughing in the children with CF relative to the range of coughing in primary ciliary 
dyskinesia (median: 5.5; IQR 3-7.3). 
Total time spent coughing in our study was substantially lower than what we had ex-
pected with a maximum of 115 sec during the fi rst night and 198 sec during the second 
night. Thus, from the above we can conclude that children with clinically stable CF are 
coughing more than normal children during the night. However, the total duration of 
cough was relatively low.
Surprisingly, cough during the 1st night did not correlate to cough during the 2nd night. 
This suggests that within subjects cough can vary considerable from night to night. Two 
possible reasons for this lack of correlation present themselves. First, cough frequency 
was too low and so insensible to measure correlation. Second, multiple causes, like gas-
tro-oesophageal refl ux may underlie cough in CF.23 We observed a variable correlation 
between lung function parameters and cough for the two nights. This most likely can be 
explained by the combination of the variability in the cough measurement and chance. 
In other studies lung function parameters did not correlate with the cough frequency, 
probably as a result of variability in cough.22,24. In contrast, PFT parameters after the 1st 
recording night correlated well to those after the 2nd night. FEF75 %pred is signifi cantly 
related to cs/h for both nights when analysed simultaneously. FEF75 %pred is more sen-
sitive than FEV1 %pred to changes in the peripheral airways, which are involved early 
in the course of disease.25 The night-to-night cough variability raises a question about 
the sensitivity of nocturnal cough as an endpoint in clinical studies. In future studies 
the minimum number of nights needed to compute a reliable mean should be investi-
gated. Furthermore, the low cough frequency in many children also raises the question 
if cough is a reliable outcome measure for example in CF treatment studies, because 
most of the children cannot ‘improve’ their nocturnal cough frequency. In one study in 
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children with a pulmonary exacerbation no change in diurnal and nocturnal objective 
cough frequency could be found after treatment with antibiotics.24 
A striking observation was that nocturnal cough dominated in the fi rst hour of sleep and 
that frequency then decreased with time. Less coughing later during the night might be 
the result of reduced cough refl ex26 or depressed mucociliary clearance during sleep27. It 
has been shown in other studies that nocturnal cough is lower than diurnal cough.3,12,28,29
A limitation of our study is that we do not know for sure whether this increased cough 
was present before and / or after the children fell asleep. For obvious logistical reasons 
the audio recording was started when children were put to bed. The cough registration 
was started when the children did not produce any noise. We think it is likely that this 
moment is close to the moment that the children fall asleep. However, this has never 
been systematically studied.
Therefore, it might be useful in clinical studies to analyse cough in the fi rst hours sepa-
rately from cough in the consecutive hours. 
In our study age and nocturnal cough are correlated; i.e. the older the child the more 
the child coughed. The most likely explanation for this correlation is that lung disease is 
more severe in older patients. We showed previously that structural damage CT scores 
progresses with age.30 Indeed, for the present cohort we observed a trend for a posi-
tive correlation between the bronchiectasis score and the cs/h; suggesting that cough 
frequency is linked to severity of CF lung disease. 
The moderate correlation observed between objective cough measurement and the 
subjective night time CSS, is in accordance with other studies in children with CF and 
also in children with asthma.3,5,31,32 In our study seven children were coughing more than 
once during one or more hours. Their CSS scores were 1 or 2 (table 1) rather than 3 or 
higher, which would have refl ected the true cough frequency. It would seem they are 
mostly not aroused from sleep by coughing, and therefore underestimate their noctur-
nal cough. For this reason the subjective CSS for nocturnal cough cannot replace the 
objective cough measurement. In another study in children with CF it was concluded as 
well that these children did not assess their night time cough frequency well.24 
In this study we cannot exclude that the nebulisation of placebo infl uenced our obser-
vations to some extent. However, we think this is unlikely since the placebo for DNase 
that we used has been used in many studies and is considered ineffective to affect mu-
cociliary clearance or cough.33 
In conclusion, the frequency of nocturnal coughing in children with clinically stable CF 
was substantially higher than that is described for normal children. In addition, noc-
turnal cough tended to be more severe in patients with more advanced disease as 
indicated by lung function parameters. Nocturnal cough was more severe in the fi rst 
hour of sleep and varied considerably from night-to-night. To use nocturnal cough as 
an endpoint in clinical studies its night to night variability should be taken into account. 
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More studies are needed to assess if cough frequency is sensitive to treatment changes 
and to determine the optimal number of nights that have to be assessed before noctur-
nal cough counting in CF can be used as a reliable surrogate endpoint in clinical studies.
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ABSTRACT
Background
Hypoxemia during sleep is a common fi nding in Cystic Fibrosis (CF) patients with more 
advanced lung disease. Nightly hypoxemia is associated with frequent awakenings and 
poor sleep quality. For children with CF, data of nocturnal oxygen saturation are sparse.
Objective
To assess the oxygen saturation profi le during sleep in 25 clinically stable children with 
early CF lung disease and to correlate these data with spirometry, cough frequency, 
sleep quality and CT-scan scores.
Method
During two nights cough was recorded with a digital audio recorder in 25 clinically 
stable CF patients (mean age 13 years; range 6-19). In addition oxygen saturation was 
measured. The day following the recording spirometry was carried out. CT scores were 
obtained from the most recent routine CT scan. 
Results
22 patients were included in the study. Mean age (range) was 13 (6-18) years. Spirom-
etry was FVC% 84 (range 52-114), FEV1% 77 (range 43-115) and FEF75% 50 (range 12-
112). The mean SO2 was 95.6% for the fi rst and 96.2% for the second night. Mean SO2 
between the two nights correlated strongly (rs=0.84, p<0.001). Positive correlation was 
observed between mean SO2 of the two nights (mean*SO2) and FVC, FEV1 and FEF75. Cor-
relations were found between mean*SO2 and the total CT score (rs=-0.45, p=0.05) and 
the bronchiectasis subscore (rs=-0.48, p=0.03). 
Conclusion
Nocturnal oxygen saturation in children with stable CF is lower than that in healthy chil-
dren, and is correlated with lung function parameters and CT scores. Monitoring oxygen 
saturation during one night is suffi cient to get a representative recording. 
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INTRODUCTION
Cystic fi brosis (CF) is characterized by chronic airway infl ammation and infection that 
start early in life and lead to airway obstruction by mucus impaction and remodeling. 
This results in gas trapping, ventilation/perfusion mismatch, higher airfl ow resistance, 
and increased work of breathing. Patients with more advanced disease may show hy-
poxemia and hypercapnia during exercise and sleep but not during daytime.1-5 How-
ever, nocturnal oxygen desaturation and reduced resting daytime oxygen saturation has 
been described in these patients as well.6 Nightly hypoxemia is associated with frequent 
awakenings and poor sleep quality. As a result these patients suffer from morning tired-
ness, chronic headache and impaired neurocognitive function.6-8 Furthermore, chronic 
or intermittent hypoxia is associated with developmental impairment, and has a nega-
tive effective on behaviour and academic achievement.9 In addition in one study it was 
shown structural lung abnormalities on CT correlated with mean nocturnal oxygen satu-
ration.10 Hence, we think that nightly oxygen saturation profi les are a clinically relevant 
surrogate endpoint that can be used in clinical studies. 
Reference values of overnight oxygen saturation are available for healthy children,11-17 
yet sparse for children older than 6 years with stable CF.10,15,18  
We therefore set out to assess nocturnal saturation profi les in children with clinically 
stable CF during two nights and to relate these saturation variables to lung function, 
cough frequency and structural lung abnormalities as established from CT scan. 
MATERIAL AND METHODS 
Study subjects
Patients followed by the CF centre at Erasmus Medical Centre – Sophia Children’s Hos-
pital were eligible for inclusion when they fulfi lled the following criteria: proven CF; at 
least fi ve years of age; ability to perform reproducible spirometry; and clinical stability. 
The latter was defi ned as no need for intravenous antibiotics and no hospitalizations 
for at least one month prior to the study. CF was defi ned as clinical symptoms charac-
teristic for CF plus an abnormal sweat test and/or by the presence of two CF mutations. 
Throughout the study, subjects continued to receive their standard treatment.
This was a sub study of a randomized controlled cross over trial in which we evaluated 
effects of administration of rhDNase or a placebo (saline 0.9%) before or after the night 
during two periods of two weeks.19 For this sub study we included the saturation profi les 
during the 7th and the 14th night in the two weeks when placebo was inhaled before the 
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night and rhDNase in the morning. Nebulisation of saline 0.9% was assumed not to 
have major effects on sputum viscosity and the nightly saturation profi le.
The Erasmus MC Medical Ethical Review Board approved the protocol. The study com-
plied with ICH-GCP guidelines. 
Procedures
Pulse oximetry
Oxygen saturation (SO2), determined by pulse oximetry (Mars pulse oximeter, Model 
2001, Respironics, Murrysville, PA, USA), was measured at home during nights 7 and 14 
in the two-weekly trial schedule. (Figure 1) The Mars oximeter has a motion artifact re-
jection system. Patients and parents were trained how to position a Y-sensorTM correctly 
at a fi nger or a toe and how to operate the oximeter in the home situation. The acoustic 
signals for pulse volumes and desaturation alarms were silenced during registration. 
Registration was started when the child went to sleep and was stopped at waking up in 
the morning. 
The SO2 signal was recorded every eight seconds and analyzed with NovaMetrix soft-
wareTM and Microsoft Excel. Total recording time (TRT) and artifact free recording time 
(AFRT) were calculated. If AFRT was less than 5 hours, the recording was excluded from 
further analysis, as it was thought not to be long enough to include at least three full 
sleep cycles.20 The mean SO2 was used for baseline calculation. Desaturation events were 
defi ned as a SO2 below ≤90% (D90) and/or a fall in SO2 relative to the mean SO2 by ≥4% 
(D4), which could appear every eight seconds. From the event data we calculated the 
total times (in seconds) of D90 (T90) and D4 (T4)as well as the oxygen desaturation index 
(ODI), defi ned as the total number of D90 or D4 per hour.
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Figure 1. Time schedule of the study.
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Pulmonary function tests
Pulmonary function tests (PFT) by means of spirometry was performed on the days 
immediately following the nocturnal oxygen saturation measurements. (Figure 1) We 
used a handheld spirometer (MicroLoop, Micro Medical Ltd, Rochester, UK). Spirometry 
was performed in triplicate according to ERS guidelines.21 The following PFT param-
eters were used for analysis: forced expiratory volume in one second (FEV1); forced vital 
capacity (FVC); and maximal expiratory fl ow when 75% of FVC was expired (FEF75). The 
values obtained were expressed as percentages of predicted values. 22 
CT score
Severity of structural lung changes was estimated using the Brody-II CT score. 23 This 
system evaluates the following qualities: bronchiectasis; airway wall thickening; mucus 
plugging; and opacities on inspiratory images as well as air trapping on expiratory im-
ages. The expiratory slices were taken at the following anatomical levels: between the 
lung apex and the top of the aortic arch, just below the carina, and at top of the dia-
phragm. Total CT scores and subscores were expressed as percentages of the maximal 
possible score on a scale of 0 (no disease) to 100 (maximal lung disease). The CT scan 
obtained at a patient’s most recent annual routine evaluation was scored. All scans were 
de-identifi ed and randomly scored by one experienced, independent observer who was 
blinded to clinical background of the scans.  
Cough recording
Nocturnal cough was recorded simultaneously with the oxygen saturation measure-
ments. Sound was recorded (32 bits mp3 format) using a digital audio player/recorder 
(ArchosTM Gmini 120, China). The recorder was positioned on a stable surface as close as 
possible to the patient. Cough recordings were transferred from the digital recorders to 
a personal computer. Recordings were analyzed using free software (Audacity, Boston, 
USA). First, cough episodes were identifi ed during which at least one explosive cough 
was present. Next, duration (in seconds) of each cough episode was computed. Finally, 
durations of cough episodes for that night were summed and divided by the total time 
of the recording. Cough frequency was thus expressed in seconds of cough per hour 
(cs/h). If several cough sounds occurred successively, duration of the timeframe in which 
these sounds fell was counted. 24 
Diary
The children were asked to keep a diary for every day of the second trial week. They 
scored sleep quality on a visual analogue scale (VAS).25 This is a horizontal line, 100 mm 
in length, anchored by word descriptors at each end. Rating is by placing a mark on 
this line in the position that best represents the child’s perception. The VAS score is the 
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distance in cm between ‘no symptom’ (left = 0 cm) and the mark placed by the child. 
The children marked on the line the point that represents best their perception of sleep. 
A low VAS score indicated good sleep quality.
Data analysis
Statistical analysis was performed with SPSS version 11.0.
Variables that were not normally distributed are expressed as median values. Relations 
between mean SO2 on the one hand, and lung function, cs/h and desaturation param-
eters (T90, D90, D4, T4, ODI4, ODI90) on the other hand were evaluated for the two study 
nights using repeated measures ANOVA. Spearman rank correlation coeffi cients (rs) 
were used to examine relations between mean oxygen saturation and age and the CT 
score. For this analysis we used the average of the two mean oxygen saturation values 
of the two nights defi ned as mean*SO2. The mean outcomes of the VAS score obtained 
during the second week were used for analysis. 
The cough seconds per hour, T90, D90 and ODI90 were log transformed to get approximate 
normal distributions. Differences were considered signifi cant at a value of p<0.05.
RESULTS
The CF-centre at the Erasmus MC-Sophia Children’s Hospital follows 152 CF-patients. 
Forty-nine of them did not meet the study inclusion criteria. The project statistician sorted 
the remaining eligible 103 children in a random order. The fi rst 43 were invited to partici-
pate in the study. Of these, 13 declined to participate, and 5 did not respond. The study 
group therefore consisted of 25 children. Analysis was done on the data of 24 children, 
as one child was withdrawn from the study due to a common cold. The fi rst saturation 
measurement was successful in 22 of the 24 patients: two patients were excluded from 
analysis since the AFRT was less than 5 hours. The second measurement was successful in 
20 patients: for two patients AFRT was less than 5 hours and for two patients data record-
ing had failed, probably due to faulty fi tting of the fi nger probe. Data of 22 children were 
included in the fi nal analysis. Table 1 shows characteristics of these children. 
Desaturation
Saturation parameters and their correlations are summarized in Table 2. During the fi rst 
night 18 out of 22 children (82%) had one or more D4 events (range 1-50) and 12 chil-
dren (55%) had one or more D90 events (range 1-85). During the second night 11 out of 
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20 children (55%) had one or more D4 events (range 1-76) and 8 children (40%) had one 
or more D90 events (range 1-107). 
Mean SO2
For each patient the mean value of the recorded SO2 was determined. The mean of these 
mean SO2 across patients was 95.6% for the fi rst night and 96.2% for the second night 
(Table 2). Mean SO2 in the fi rst night correlated strongly (rs=0.84, p<0.001) (Figure 2a) 
with that in the second night, however the agreement between the two was moderate 
(ICC=0.70). The Bland Altman suggests that the variability is somewhat less for the lower 
mean SO2.(Figure 2b)
Repeated measures ANOVA showed that the relations between mean SO2 versus PFTs 
(FVC, FEV1 and FEF75 %pred) and the resting SO2 did not signifi cantly differ between the 
Table 1. Baseline characteristics of the study population (n=22). Numbers are expressed as mean 
(range).
Sex (male/female) 7 / 15 
Age (years) 13 (6.3-18.7)
FVC %pred 84 (52-114)
FEV1 %pred 77 (43-115) 
FEF75 %pred 50 (12-112) 
Brody CT score (%) 13 (0-37)
Bronchiectasis score (%) 13 (0-47)
Table 2. Saturation parameters and recording time (median (range)) for nights 1 and 2 separately. 
The right-hand column shows correlations between the two nights (rs,p). ‡= p<0.05   
Night 1 Night 2 Correlation (rs,p)
Mean saturation (%) 96.2 (90.1-97.6) 96.3 (92.9-98.2) 0.84, <0.001‡
AFRT (min) 530 (300-736) 574 (383-715) 0.50, 0.02 ‡
TRT (min) 579 (300-745) 573 (383-720) 0.60, 0.01 ‡
D4 2 (0-50) 1(0-76) 0.37, 0.11
ODI4 0.2 (0-9.9) 0.1 (0-8.0) 0.44, 0.05
T4 (sec) 12 (0-2928) 60 (0-4288) 0.30, 0.19
D90 1 (0-85) 0 (0-107) 0.35, 0.14
ODI90 0.1 (0-8.9) 0.0 (0-11.2) 0.36, 0.12
T90 (sec)  8 (0-8376) 0 (0-4816) 0.39, 0.88
Abbreviations: AFRT: artifact free recording time; TRT: total recording time; D4:Fall in SO2 by ≥4%; D90: Fall in SO2 
to ≤90%; ODI4: Oxygenation desaturation index per hour of D4; ODI90: Oxygenation desaturation index per hour of 
D90; T4: total time in seconds of D4; T90: total time in seconds of D90
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two evaluated nights. For further analysis we therefore used the mean SO2 of the two 
nights defi ned as mean*SO2. 
A positive correlation was observed between mean*SO2 and FVC. For a decrease of FVC 
%pred by 10 percentage points, the mean*SO2 decreased by 0.6 percentage points high-
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Figure 2. 
a) Correlation between mean oxygen saturation of the 1st versus the 2nd night. Line represents line of identity.
b)  Bland-Altman Plot. The differences in mean oxygen saturation (SO2) of night 1 and 2 plotted against the averages 
of the two measurements. Top and bottom and horizontal lines represent +/-2 standard deviation (-2.46 to 1.70). 
Line in the middle represents the mean difference (-0.38).
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er (p=0.007; 95% CI 0.2%-1%). For a decrease of FEV1 and FEF75 by 10% the mean*SO2 
decreased by 0.5% (p=0.004; 95% CI 0.2%-0.7%) and 0.3% (p=0.02; 95% CI 0.1%-0.5%) 
respectively. (Figures 3, 4 and 5) 
There was no signifi cant correlation between mean*SO2 and *cs/h (p=0.81) when evalu-
ating both nights. 
There was a moderate correlation between the mean*SO2 and the total CT score (rs=-
0.45, p=0.05) and the bronchiectasis subscore (rs=-0.48, p=0.03). No signifi cant corre-
lation was found between mean*SO2 and the air trapping subscore (rs=-0.18, p=0.94). 
Also no correlation was found between mean*SO2 and age (rs=0.29, p=0.22).
Sleep quality
We could not establish signifi cant correlations between the subjective VAS score sleep 
quality and saturation parameters. The TRT was moderately correlated with the VAS 
score sleep quality (rs=-0.45 p= 0.05). 
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Figure 3. Scatter plot of mean oxygen saturation versus FVC %pred for the two study nights. Lines 
represent regression lines; no signifi cant difference between the two evaluated nights.
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Figure 4. Scatter plot of mean oxygen saturation versus FEV1 %pred for the two study nights. 
Lines represent regression lines; no signifi cant difference between the two evaluated nights.
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Figure 5. Scatter plot of mean oxygen saturation versus FEF75 %pred for the two study nights. 
Lines represent regression lines; no signifi cant difference between the two evaluated nights.
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DISCUSSION
In this study we recorded SO2 profi les during two nights in children with clinically stable 
CF. The mean values were 95.6% and 96.2%, respectively, and thus lower than what has 
been reported 96.5-99.3% for healthy children. 11-13,15-17 In addition, we found correla-
tions between mean SO2 and other parameters of disease severity, such as lung function 
and CT scores. 
The oxygen saturation we observed is comparable to that reported for a group of 72 CF 
patients aged 1-18 years (mean SaO2 96.1%) in 2004 and for a group of 24 patients aged 
8-13 years (mean SaO2 96.1%) in 2007, but slightly higher than that for a group of 24 CF 
patients aged 10-22 years (mean SaO2 94%) in 1990.
10,15,18 The latter might be explained 
by the younger age of our  subjects and by a better clinical condition of patients today 
relative to 17 years ago. The subjects in the study by Versteegh and colleagues in 1990 
had a mean FEV1 of 57% (range 24-111), which is 20% below that of the patients in 
our study. The strong correlation (rs=0.84) between the two study nights we found for 
oxygen saturation is in accordance with the fi nding of Versteegh and colleagues, who 
found a correlation of rs=0.83. This would seem to implicate that for the mean SO2 the 
recording of one night is in general suffi cient to get a representative recording. But, 
using the mean SO2 based on one night, gives a chance for missing low mean SO2 from 
other nights. See Figure 2. However, for desaturation parameters such as the D4 and D90 
it still might be useful to measure two nights. 
In this study we report frequency of desaturations at night in children with CF. This 
frequency ranged from 40-55%, whereas D90 events were reported in no more than 3 to 
37% of healthy children.11-14 Hence, children with CF seem to have more desaturation 
events than healthy children, which is similar as in the study of Uyan et al.10 
In this study a correlation was found between lung function parameters and the mean 
SO2, which confi rms previous observations.
4,10,18,26,27 Versteegh and colleagues found a 
FEV1% of ≤ 65% to be associated with nocturnal desaturation, defi ned as SO2 ≤ 90%.
18 
In a study in adults with CF no thresholds were found that could reliably predict de-
saturation during the night.4 The same was true for our study. In the fi rst night 5 out of 
6 children with a FEV1 ≤65 %pred had D90 events. Yet, 7 of the 16 children with a FEV1 
>65% also experienced D90 events. Although all children with a FEV1 %pred >82% had a 
mean SO2 >96%, 67% of these children had D90 events during the fi rst night. Therefore, 
although lung function parameters are correlated with oxygen saturation, they are of 
limited use in predicting desaturation periods. See Figure 6.
In this study nocturnal saturation was correlated with CT scores. We showed that low 
mean saturation is associated with structural lung damage, as refl ected by a high total 
CT score or bronchiectasis subscore. This correlation is comparable with one other study 
in children with CF aged 8-13 years. They found a correlation of 0.67 between total CT 
Lianne BW.indd   91 10-07-09   11:13
92 Chapter 6
score (using the Helbich score) and oxygen saturation.10 Two other studies showed cor-
relation coeffi cients from 0.35 to 0.57 between mean SO2 and chest radiographs.
4,10,15 In 
one of these, CF patients had a mean FEV1 of 58% (range 21-113).
4 The other study does 
not provide details on lung function measurements. Structural abnormalities on CT are 
considered an important surrogate endpoint for refl ecting the severity of CF lung dis-
ease.28 Our fi ndings in this cross sectional study suggests that reduced nocturnal oxy-
gen saturation in stable CF patients can be an indicator of structural abnormalities on 
CT. However, the air trapping subscore did not correlate with the mean*SO2. This can be 
explained by the fact that we used only 3 expiratory slices to estimate the severity of air 
trapping. Recently, we showed that the use of only 3 slices underestimated the severity 
of air trapping for the Brody II score and increased the variability of the mean air trap-
ping score. In addition, we did not use a controlled volume procedure, which may have 
introduced some extra variability in the estimate of the severity of air trapping.29 Finally, 
air trapping as observed on CT may not be related to ventilation perfusion mismatch. 
Further longitudinal studies would be needed, however, to establish whether nocturnal 
oxygen saturation is able to track CF disease progression as accurately as CT.  
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Figure 6. Relationship between FEV1 %pred and desaturation events during the fi rst night. Note: 
Area left of the vertical line represents FEV1 <65 %pred, reported to be associated with nocturnal 
desaturation.18 
D90= Fall in oxygen saturation to ≤90%. 
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We think it is highly relevant to monitor nocturnal oxygen saturation more closely in CF. 
It has been well recognised that sleep problems may have signifi cant effects on daytime 
functioning.5,7 In addition, even milder levels of desaturation have been associated with 
lower IQ and Attention Defi cit Hyperactivity Disorder symptoms in children with other 
disorders than CF.9 As shown by our results even stable CF patients have suboptimal 
nocturnal oxygen saturation and thus might be at risk for such disorders. Currently it is 
unclear what level of oxygen desaturation becomes important during sleep.30 Clearly, 
the relation between subnormal oxygen saturation profi les in CF on sleep quality, IQ 
and behaviour needs to be further investigated. 
The potential value of saturation profi les as an objective endpoint to evaluate the ef-
fect of therapeutic interventions has not been studied systematically. We speculate that 
the observed suboptimal nocturnal saturation profi les refl ect especially peripheral air-
way obstruction as indicated by the reduced FEF75. Intravenous antibiotic treatment and 
rigorous physiotherapy are likely to improve nocturnal saturation. Nocturnal oxygen 
saturation could even be a more clinically relevant surrogate endpoint than spirometer 
derived parameters in relation to the importance of good sleep quality. 
In conclusion, oxygen saturation in children with stable CF is lower than that in healthy 
children, and is correlated with lung function parameters and CT scores. Monitoring 
oxygen saturation during one night is suffi cient to get a representative recording. While 
desaturation periods were observed in some patients with well-preserved lung function, 
it did not occur in other patients with more advanced disease. 
The value of nocturnal oxygen saturation as a surrogate endpoint should be further 
investigated in longitudinal interventional studies in larger cohorts.  
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ABSTRACT
Background 
Airway clearance therapy (ACT) is used to improve expectoration in children with Cystic 
Fibrosis (CF). So far no gold standard is available to evaluate the effi cacy of ACT. Re-
sistance of the respiratory system can be measured with Interrupter technique (Rinte). 
Object
To assess the feasibility and sensitivity of Rinte to detect changes in airway resistance in 
relation to ACT 
Methods 
Rinte was performed directly before and after ACT in children with CF. The difference in 
Rinte (ΔRinte) was used as a measure of response to ACT. 
Sputum production was estimated with a semi quantitative scoring system. 
Results
Eighteen children participated. Mean age (range) was 15 (7-19) years. ΔRinte correlated 
with the sputum production score during ACT (rs=0.67, p=0,002) and with the daily 
sputum production score (rs=0.62, p=0.007) 
Conclusion 
Rinte tends to improve after ACT and is negatively correlated to the sputum production. 
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INTRODUCTION
Airway clearance techniques (ACT) are considered cornerstone therapy in Cystic Fibrosis 
(CF) to improve mucociliary clearance.1 Approximately 90% of all CF patients use some 
form of ACT.2, 3 A Cochrane review demonstrated ACT to be effective in increasing mucus 
transport in the short term. No evidence was found with respect to long-term effects. 
Endpoints in the reviewed studies were sputum weight, total lung capacity, functional 
residual capacity and transport rate of radioactive tracers.4
A clinical applicable gold-standard method for evaluating the short-term effi cacy of 
ACT in children with CF is still lacking. Combined measurement of mucus transport – us-
ing radioactive tracers – and expectorated mucus volume is probably the most reliable 
method to date.1, 5, 6 The use of radioactive tracers in clinical practice, however, raises 
ethical concerns, and is technically diffi cult. Therefore, they are not a suitable outcome 
parameter. Monitoring of sputum weight or volume has its drawbacks as well. Patients 
often are reluctant to expectorate and there is the risk of inadvertent swallowing of 
secretions and of contamination of the secretions by saliva.5 Furthermore, in younger 
children expectorated sputum is often not available and cannot be used as a study 
endpoint. 
Standard pulmonary function tests, such as fl ow volume measurement, were frequently 
used to evaluate chest physiotherapy effectiveness.5 However, the measurement of air-
fl ow and simple lung volumes do not appear to refl ect changes in mucus transport and 
are relatively insensitive to airway clearance manoeuvres. For this reasons these tests 
are considered to be inadequate to evaluate ACT in short term studies. 5 A promising 
observation was that ACT has a positive effect on specifi c airway conductance (sGaw) as 
measured by plethysmography 7 suggesting a positive effect of ACT on central airway 
clearance.8, 9 An alternative and easier tool to measure respiratory system resistance 
may be the interrupter technique or Rint.10 Rint is sensitive to changes in airway cali-
bre in children with mild respiratory tract infections and can be performed quickly in 
the ambulatory setting.11 Rinte measurements have been shown to be reproducible.
12 
Validation studies against measurement of airway resistance with body plethysmograph 
showed a good correlation between the two methods.12, 13 We performed a study to as-
sess whether Rint is a feasible tool for ACT studies, hypothesizing that ACT clears out 
mainly central airways and thus lowers airway resistance as measured by Rint. 
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MATERIAL AND METHODS
Study subjects
Eligible subjects were children with CF aged 6 years or older, hospitalized for pulmonary 
exacerbation in Erasmus MC Sophia Children’s Hospital in Rotterdam, the Netherlands 
and who were able to perform ACT. Exclusion criteria were: inability to perform repro-
ducible pulmonary lung function tests; being in the process of learning a new form of 
ACT; inability to expectorate sputum.
Study design
Rint measurements were done before and after routine ACT in the fi rst week of a hos-
pital admission for a pulmonary exacerbation. ACT techniques used are shown in Table 
1. Children were asked to score their daily sputum expectoration score (DSE) by a semi-
quantitative scoring system, ranging from 0=no sputum to 3=more than a cup of spu-
tum a day (Table 2). The physiotherapist, who performed the ACT, documented the “ACT 
related sputum expectoration score” (ASE) using a semi quantitative scoring system 
ranging from 0=no sputum to 4=more than 10 times sputum expectoration during ACT 
(Table 3). Duration of ACT was standardized 30 minutes. Pulmonary function tests (PFT) 
were carried out in the fi rst week after admission.
Table 1. Form of ACT
N / %
PEP mask 4 / 22%
Autogenic drainage 9 / 50%
Flutter® VRP1 2 / 11%
Combination 3 / 17%
Table 2. Daily sputum expectoration score (DSE) 
Score Description N  / %
0 nothing – one tablespoon a day 3 / 16
1 one tablespoon – half a cup 10 / 56
2 half a cup – 1 cup 5 / 28
3 more than a cup 0 / 0
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Equipment specifi cations
We used the MicroRint (Micro Medical Ltd, Rochester, UK), a portable device connected 
to a palmtop computer. MicroRint has an online display showing: mouth pressure; time 
of shutter closure; Rint values; and median value of all Rint data recorded during one 
session. Measurements of the interrupter resistance (Rint) are based on measurements 
of tidal airfl ow before and mouth pressure after closure of a fast shutter. The ratio be-
tween the pressure difference and airfl ow equals the interrupter resistance and refl ects 
respiratory resistance. 
Pulmonary functions tests (PFT) were done using a Jäger diagnostic system (Masterlab, 
Jäger, Germany). Flow was calibrated daily using a 1-L precision pump. The following 
PFT results were obtained: forced expiratory volume in one second (FEV1); forced vital 
capacity (FVC); and expiratory fl ow at 25% of the actual forced vital capacity (MEF25). 
Spirometry was performed in triplicate according to ERS guidelines.14 The PFT results 
were expressed as a percentage of predicted values.15
Procedure
The physiotherapist was trained by a certifi ed lung function technician until she was 
able to perform the Rint measurements according to their standards. Rint measure-
ments were carried out in the morning in the patient’s room by one investigator (LG). 
Children were asked to sit quietly for 10 minutes prior to the procedure and then clear 
their throat by coughing. The hands of the investigator supported the patient’s cheeks 
and chin to reduce upper airway compliance.16 To accustom the children to the sound 
of the shutter its functioning was demonstrated to the children before the actual mea-
surements. Children were instructed to sit upright and breathe quietly during measure-
ments. Next, a minimum of 5 and a maximum of 10 correct tracings were collected dur-
ing the expiratory phase (Rinte) of the breathing cycle. A correct tracing consisted of a 
regular breathing pattern and a consistent shape of the mouth pressure-time curve.17,18 
Expiratory interruptions are considered to be more sensitive than inspiratory interrup-
tions to detect intrathoracic airway obstruction.12 During Rinte measurements the head 
Table 3. ACT sputum expectoration (ASE) 
Score Description N / %
0 0 times expectorate sputum 2 / 11
1 1-3 times expectorate sputum 2 / 11
2 4-6 times expectorate sputum 4 / 22
3 7-9 times expectorate sputum 2 / 11
4 > 10 times expectorate sputum 8 / 44
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was positioned in a slight extension and a nose clip was used. The hands of the observer 
supported the cheeks and chin to reduce the effect of upper airway compliance on air-
way resistance.16,19 After this measurement routine ACT was conducted for 30 minutes. 
Finally, Rinte measurements were repeated 10 minutes after ACT completion. 
Data analysis
Statistical analysis was performed with SPSS version 10.0.
Rinte before and after ACT were expressed as median values to reduce the effect of pos-
sible outliers.20 The change in Rinte (ΔRinte) was calculated for each individual patient as 
the difference between Rinte (before)  and  Rinte (after). Hypothesizing a decrease of resistance 
following ACT, the values of Rinte (before)  and  Rinte (after) were compared using a paired T-
test. Spearman rank correlation coeffi cient (rs) was used to examine relations between 
ΔRinte, lung function, age, Rinte (before), sputum production during ACT, and daily sputum 
production. Power calculation showed that 17 patients were needed to detect a correla-
tion of 0.7 at alpha is 0.05 with a power of 90%.
RESULTS
Rinte measurements could be performed without diffi culty in all 18 eligible children (7 
male; 11 female). The distribution of DSE and ASE scores are shown in Tables 2 and 3. 
The patient characteristics are shown in Table 4. There was a trend towards a reduc-
tion of the Rinte (after) relative to the Rinte (before) (95% CI –0.005 to 0.093 kPa/L/s; p=0.07). 
Sixty-one percent (n=11) of the children impro ved their Rinte after ACT, 5% (n=1) had 
no difference and 33% (n=6) had deterioration in Rinte. The median drop in resistance 
was 6%. ΔRinte varied between –0.13 and 0.26 kPa/L/s. ΔRinte correlated signifi cantly 
with the ACT sputum production score (rs=0.67, p=0.002) (Figure 1) and with the daily 
sputum production score (rs=0.62, p=0.007) (Figure 2). Rinte (before) correlated signifi cantly 
with the daily sputum production score (rs=0.67, p=0.002). No signifi cant correlation 
was found between ΔRinte and baseline FVC, FEV1 or MEF25. The daily sputum produc-
Table 4. Patient characteristics 
Mean (range)
Age (yrs) 14.7 (6.8-19.7)
FVC (%pred) 81 (37-123)
FEV1 (%pred) 68 (31-113)
MEF25 (%pred) 26 (5-58)
Rinte (kPa/L/s) 0.60 (0.26-1.46)
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tion score and the ACT sputum production score were signifi cantly correlated (rs=0.7, 
p=0.002). 
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Figure 1. Correlation between ΔRinte and the ACT sputum expectoration score (rs=0.67, p=0.002).
'DLO\6SXWXP([SHFWRUDWLRQ

'L
IIH
UH
QF
H5
LQW
HE
HIR
UH
DQ
GD
IWH
U$
&7






Figure 2. Correlation between ΔRinte and the daily sputum expectoration score (rs=0.62, p=0.007).
Lianne BW.indd   103 10-07-09   11:13
104 Chapter 7
DISCUSSION
The objective of this pilot study was to assess the feasibility of Rinte to detect changes 
in respiratory resistance in relation to ACT. 
Rinte measurements were feasible in all eligible patients. ACT had a borderline effect on 
Rinte and changes in Rinte correlated signifi cantly with the reported amounts of expec-
torated mucus. 
The relation between Rinte (before)  and  Rinte (after) is probably not straightforward. Rinte (after) 
was even higher than Rinte (before) in the fi ve children who were not able to mobilize spu-
tum during ACT. In these patients, sputum might have been mobilized from the periph-
eral airways into the more central airways, thereby increasing central airway resistance. 
Patients with higher ASE or DSE scores had the greatest fall in respiratory resistance. 
Low sputum scores were associated with wider variability in decline of Rinte. This sug-
gests that Rinte is a more suitable outcome variable in patients with greater sputum 
production. One other study investigated the Rinte before and after ACT in children 
with CF. They found in 77% a fall in Rinte. In this study the amount of sputum was not 
measured.21
We could not demonstrate a correlation between sputum production and expiratory 
fl ow rate. Our fi ndings are in agreement with those from other studies that investigated 
the effect of ACT on lung function.7-9, 22, 23 ACT previously was shown to improve specifi c 
airway conductance (sGaw) and to reduce functional residual capacity.7, 23 However, no 
relation was observed between sputum production and sGaw increase.7 The respiratory 
resistance can be underestimated by Rinte in patients with more severe airways obstruc-
tion because alveolar pressures will be underestimated when time constants are too 
long for equilibration between alveolar and mouth pressure to occur.24 We therefore 
speculate that the difference in Rinte following ACT is underestimated in those subjects 
with more severe obstruction. 
Healthy children show 8.5% fall in Rinte after bronchodilatation.
25 Children with CF varied 
greatly in their response with Rinte after bronchodilatation. These authors conclude that 
Rinte cannot be used as a substitute for spirometry in school children with CF undergo-
ing bronchodilator challenge.26 The fall in our study was 6%, but the clinical relevance 
of this order of magnitude for children with CF cannot be confi rmed at this moment. 
We have assumed a causal relationship between the measured difference in Rinte and 
ACT. However, we assume that the observed differences might not have been related 
to the mobilization of sputum, but rather to, for example, physiological fl uctuations of 
Rinte. 
For future studies we recommended to combine measurement of Rinte with Sgaw mea-
surement or with measurements of ventilation inhomogeneity, so as to exclude other 
explanation for the observed fl uctuations in resistance. Measurement with forced ex-
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piration manoeuvres are not recommended because they can result in sputum expec-
toration and thus infl uence the respiratory resistance. Then, our study design did not 
provide for blinding of the investigator for timing of ACT. In future studies it would be 
important to blind the investigator for the timing of ACT. Another limitation of our study 
is that Rinte was only compared to a non-validated semi–quantitative scoring system for 
sputum volume; sputum weight or volume did not serve as a golden standard. Because 
it is easy in use, cheaper than monitoring sputum weight and gives a suffi cient insight in 
the amount of sputum evacuation of the patient, it is worthwhile to validate this scoring 
system with sputum weight or volume in the future. 
In conclusion, Rinte is a feasible method that may serve as an outcome variable for 
short-term ACT studies. Rinte tends to improve after ACT and is negatively correlated to 
the sputum production. 
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ABSTRACT
Introduction
More than half of the pediatric Cystic Fibrosis (CF) population is non-adherent to CF 
treatment. Inadequate knowledge of the disease and treatment are factors that might 
infl uence compliance negatively. To increase patients’ knowledge about CF lung disease 
we developed a board game named ‘Airway’. The effect of playing ‘Airway’ was evalu-
ated in a randomized controlled study. 
Objective
To increase pediatric CF patients’ knowledge of CF lung disease. 
Patients and methods
‘Airway’ is played by a pediatric physiotherapist and one child. To study the effect on 
knowledge by playing ‘Airway’ we performed a randomized controlled study. Inclusion 
criteria: proven CF, age 7-13 years. Children were randomized into two groups. Both 
groups were assessed twice with a written knowledge questionnaire including 16 mul-
tiple choice questions about airways, CF and treatment. Only children in the interven-
tion group played ‘Airway’ in between the two questionnaire rounds.  
Results
Thirty-seven children participated, 17 in the intervention group, 20 in the control group. 
Patient characteristics: boys n = 9 and 10, mean age 10.5 (range 8-13) and 10 (8-13) 
years, respectively. The mean percentage of correct answers to the questionnaire in-
creased by 13% for the intervention group and by 5% for the control group (p=0.03). 
Conclusion
Playing the board game ‘Airway’ increases children’s knowledge about CF lung disease.
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INTRODUCTION
Cystic fi brosis (CF) is the most common autosomal recessive disease in the Caucasian 
population. It is a complex illness, involving many organ systems such as the respiratory 
and gastro-intestinal tracts. In the lungs, CF is characterized by abnormal mucus accu-
mulation. As a result the airways become chronically infected with bacteria, so that lung 
function progressively deteriorates.1 This eventually leads to premature death due to res-
piratory failure in the majority of the patients. Treatment of the airways is initiated imme-
diately after diagnosis and has to be continued life long. Treatment intensity is stepped 
up gradually with increasing age and generally represents a great burden to the patients.2 
Home treatment for CF lung disease consists of oral and nebulised antibiotics, daily air-
way clearance therapy (ACT) and physical exercise, and nebulisation of mucolytics such 
as rhDNase and hypertonic saline. In addition most patients have pancreatic insuffi cien-
cy and thus require daily pancreatic enzymes and vitamins. Compliance to treatment 
is an important factor that determines morbidity and mortality.3 Not surprisingly, the 
highly complex nature of CF treatment is a major challenge to compliance. Up to 50% of 
pediatric populations have been found non-adherent to their CF treatment regimens.4, 5 
Compliance rates for ACT in children range from 40 to 75% 5-7 and for nebulisation with 
rhDNase from 57 to 90% 6, 8. Compliance is a complex issue affected by variables such 
as: age, inadequate knowledge; psychosocial resistance and cognitive functioning.9, 10
Both knowledge of the disease and treatment regimen and understanding of the back-
ground of the physicians’ treatment recommendations are thought to be critical to 
compliance. Substantial gaps in knowledge about CF lung disease have been identifi ed 
in children and their parents.11 In two studies the level of compliance among children 
with CF was positively associated with the level of their knowledge of the disease.12, 13 In 
another study no such relationship was found.11  
We aimed to test a purpose-developed instrument which could potentially increase 
children’s knowledge about their CF lung disease: a board game named ‘Airway’. We 
hypothesized that playing this game would increase children’s knowledge about their 
CF lung disease. 
MATERIAL AND METHODS
Board game
‘Airway’ was developed in close collaboration with primary education teacher-training 
college “Thomas More” (Rotterdam, the Netherlands) and educational publisher Xplore 
(Hoevelaken, the Netherlands). The language of ‘Airway’ is Dutch, but during develop-
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ment we took into account that easy translation in other languages would be feasible. 
‘Airway’ is played by the child and a trained physiotherapist, and involves tasks and 
questions focussed on CF, sputum physiology, infection and treatment. Interaction and 
discussion are facilitated during the game. ‘Airway’ takes approximately 45 minutes to 
play. Figure 1 shows an example of one of the tasks.
 
  
 
Figure 1. Example of task ‘place the pictures in the right order’ in the board game ‘Airway’.
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Knowledge test
To test children’s knowledge level of CF lung disease a dedicated Knowledge Question-
naire (KQ) was developed in close collaboration with primary education teacher-training 
college “Thomas More” (Rotterdam, the Netherlands). It consists of 16 multiple-choice 
questions with each three possible answers. The questions are focussed on lung func-
tion and anatomy, the effect of CF on the lungs, and treatment of CF lung disease. Ques-
tions about emotional aspects of the disease were not included in the KQ. The KQ was 
tested in six healthy primary school children aged 7 to 13 years. These children were 
asked to provide feedback on the wording of the questions. 
Study subjects
Patients followed by the CF centre at the Erasmus MC – Sophia Children’s Hospital were 
eligible for the study when they met the following criteria: proven CF, age between 7- 13 
years. CF was defi ned as clinical symptoms characteristic for CF plus an abnormal sweat 
test and/or the presence of two CF mutations. Patients with severe mental retardation 
were excluded from this study
Study design
The study had a randomized controlled design. Children who met the inclusion criteria 
were invited by letter to participate in this study. After informed consent by the parents 
and when applicable by the older children (>12 years) the subjects were randomized 
to either an intervention group (I) or to a control group (II). Children enrolled in the 
intervention group came from the south-western Netherlands, children enrolled in the 
control group from the area north of Rotterdam. Both areas are demographically com-
parable.
All subjects received the KQ by mail and were asked to return it within one week. An ac-
companying letter asked parents not to assist the children in completing the questions. 
Next, a pediatric physiotherapist (SOS) with CF experience scheduled appointments 
with the children assigned to the intervention group, intended to play ‘Airway’; these 
appointments were planned within one week after the KQ was completed. Children as-
signed to the control group did not play the game. Thereupon all subjects were asked 
to complete the KQ again within one week. The pediatric physiotherapist (SOS) who 
played the game was blinded to the responses to the fi rst KQ. The time interval between 
the two KQ’s was the same for intervention group and the control group.
The Erasmus MC Medical Ethical Review Board approved the protocol. The study was 
performed according to ICH-GCP guidelines. 
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Data analysis
Primary outcome variable was the change from baseline of the % correct answers to 
the questions in the KQ. The Mann-Whitney test was used to compare the difference 
of these changes between the study groups. Within groups analysis of the number of 
correct answers was done using Wilcoxon Signed Rank Test. Spearman correlation coef-
fi cients were used to investigate associations between lung function parameters and 
age versus the baseline KQ scores.
Statistical analysis was performed with SPSS version 11.0, and P=0.05 (two-sided) was 
considered the limit of signifi cance in all analyses.
RESULTS
Of the 152 children followed by the CF centre, 47 met the inclusion criteria and were 
invited by letter to participate. Four children (8%) did not respond and six children (13%) 
declined to participate. Hence, the total study group included 37 children (79%), 
17 of whom were enrolled in the intervention group and 20 in the control group 
Baseline characteristics are summarized in Table 1. The groups did not differ signifi -
cantly regarding distribution of age, lung function and sex. 
The mean number of correct answers in the intervention group increased signifi cantly 
(p=<0.001) from 12.9 (range 7-15), to 15.1 (range 13-16) after playing ‘Airway’. The 
mean number of correct answers in the control group did not increase signifi cantly 
(p=0.08) from 13.4 (range 5-16), to 14.2 (89%; range 8-16). Hence, the mean percentage 
of correct answers increased signifi cantly more in the intervention group as compared 
to the control group: 13% and 5%, respectively (p=0.03). Figure 2 shows individual out-
comes of the study.
Table 1. Patient characteristics
Characteristics of the study population (numbers of patients or median with range) for Group I and group 2. Group 1 
played the board game ‘Airway’; group 2 did not play the game. 
Group 1 Group 2 p-value*
N 17 20 NS
Sex (male/female) 9 / 8 10 / 10 NS
Age (year) 11.0 (8.0-12.8) 9.9 (7.9-12.9) NS
FVC (% predicted) 88 (66-120) 88 (48-117) NS
FEV1 (% predicted) 85 (53-122) 87 (43-119) NS
MEF25 (% predicted) 45 (10-105) 43 (12-131) NS
* P-value according to Mann-Whitney test
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Children were generally knowledgeable about general items, such as location of the 
lungs, how to get as much air as possible in the lungs, function of cough and the pres-
ence of viscous sputum in CF. But also they showed major gaps in their understanding 
of the disease. For example, 18 (49%) children thought that swallowed sputum went 
back into the lungs, 19 (51%) were not aware that airways are smaller toward the pe-
riphery, 19 (51%) were not aware of the role of the abdominal muscles to cough up 
sputum effectively, and 5 (14%) children guessed that sputum in the lungs eventually 
would be eaten by bacteria.
No signifi cant correlations were found between lung function parameters and age ver-
sus the percentage of correct answers. 
DISCUSSION
In this study, children who were playing the board game ‘Airway’ showed signifi cantly 
improved knowledge about CF lung disease as compared to a control group. This fi nd-
ing confi rms the results of another study that aimed to increase knowledge about CF 
lung disease within the framework of a self-management program.14 In this study the 
higher knowledge level was maintained at follow-up 12 months later. 
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Figure 2. Numbers of correct answers to the 16 items of Knowledge Questionnaire (KQ) round 
1 and 2. Children in group 1 played the board game ‘Airway’ between the two KQ rounds. Lines 
connect individual data points. Bars represent mean values.
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The baseline fi ndings of our study showed that the children in our centre were relatively 
well informed about lung issues in relation to CF with a mean number of 13.2 correct 
answers out of 16 questions. Nevertheless some important misapprehensions were de-
tected. The children in our centre seem to be much better informed about their disease 
than two decades ago. Our results thus clearly differ from those of a South African study 
in 1990 which concluded that patients’ knowledge was poor.15 In another study from 
1996 adult patients had – comparable to our study – good general baseline knowledge 
about the lungs but misconceptions were observed.16 A good baseline level of knowl-
edge may be related to better possibilities to obtain information from the Internet, and 
the availability of other educational materials. In addition, CF teams today are likely to 
be more motivated to explain the pathophysiology of CF lung disease to their patients. 
Clearly, the results of this study are center specifi c. Both the KQ and the board game can 
be useful tools to systematically evaluate the level of education within different centres. 
As stated, the KQ and the board game have been designed in such a way that translation 
and validation into other languages will be relatively easy.  
Importantly, playing ‘Airway’ with the children allowed the physiotherapist to go over 
basic elements of CF lung disease in a systematic and joyful fashion. It proved to be a 
useful tool to facilitate interaction and discussion about the therapy. It gives the phys-
iotherapist an excellent opportunity to teach the children the benefi ts and necessity of 
the therapy and to learn about specifi c gaps in the knowledge of individual patients. 
By educating individual patients about their current physical condition and progression 
of disease, the physiotherapist may stress the necessity of therapy compliance, without 
causing the patient to get overly concerned.17 Generally, continuous educational dia-
logue with the patient about the treatment will empower the patient to take ownership 
for treatment.18 
Another advantage of ‘Airway’ is that relatively young children of seven years and older 
can play the game. We believe that it is important to teach young children about the im-
portance of therapy compliance and to train them in taking some responsibility for their 
treatment before reaching adolescence. Throughout adolescence children should move 
towards complete control over their lives. The tendency in adolescents to rebel against 
authority often results in problems with compliance in this particular age group.12,18 
Playing ‘Airway’ takes around 45 min per child. We feel strongly that this is time well 
spent. 
Daily aerosol and ACT treatment regimens are recommended for most children with CF 
to assist the removal of excess sputum. These treatments are complex, and are associ-
ated with little immediate reward.14 In situations like these, it has proven diffi cult for 
children to understand benefi ts and necessity of treatment compliance.19 Therefore we 
believe that it is very important to ensure that children gain as much knowledge about 
CF lung disease as possible. 
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From this study it does not become clear how long the increased knowledge will persist 
and whether it results in improved compliance. There are studies, however, which sup-
port the general concept that the level of compliance among children with CF is related 
to their knowledge of the disease.12, 13
Our study showed that playing the board game ‘Airway’ increases children’s knowledge 
about CF lung disease and can help to identify specifi c knowledge gaps in the patient’s 
understanding of the disease.  
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SUMMARY
Cystic fi brosis (CF) is an autosomal recessive life-limiting disease. It is chronic and com-
plex, involving organ systems such as the respiratory tract and the gastro-intestinal 
tract. Chronic lung infection and infl ammation start early in life and result in airway wall 
thickening and plugging of bronchioles with purulent secretions.
The primary aim of therapy in CF lung disease is to preserve the normal architecture of 
the lung and to prevent any damage from occurring. Its management includes frequent 
treatment with antibiotics, mucoactive drugs and airway clearance techniques (ACT). 
Treatment is lifelong, and ensuring constant adherence to the often burdensome treat-
ment regimens is a major challenge for the patient and the CF team alike. This thesis 
is focused on the timing of rhDNase inhalation and ACT, outcome measures in CF lung 
disease, as well as patient education about CF lung disease. 
Chapter 1 contains a general introduction to the thesis; Chapter 2 explains the outlines 
and aims of the studies. 
In Chapter 3 we describe a randomized, double blind, double dummy, cross over study 
performed to compare the effects of rhDNase before ACT versus rhDNase after ACT in 
25 children with CF. All children were on maintenance therapy with rhDNase. We created 
two groups. Children in group I inhaled rhDNase 30 minutes before ACT, and placebo 
directly after ACT in weeks 1-3. The protocol was reversed during weeks 4-6. The other 
group performed the reversed sequence. All children continued their daily routine ACT. 
Primary endpoint was MEF25 %pred as an indicator of peripheral airway patency. We 
concluded that inhalation of rhDNase before ACT improves MEF25 %pred in children 
with CF. 
In Chapter 4 we present the results of a second randomized, double blind, double 
dummy, cross over study. This was aimed at comparing the effects of rhDNase inhaled 
before bedtime or after waking up in 25 children with CF. All children were on main-
tenance therapy with rhDNase. We created two groups. Children in Group I inhaled 
rhDNase before bedtime, and a placebo after waking up in weeks 1-2. The protocol was 
reversed during weeks 3-4. The other group performed the reversed sequence. Patients 
performed their routine ACT 30 minutes after the nebulisation in the morning. Primary 
endpoint was MEF25 %pred as an indicator of peripheral airway patency. We found no 
signifi cant differences in lung function parameters between the study periods when 
rhDNase was inhaled before bedtime and those when it was inhaled after waking up. 
Neither did nocturnal cough frequency, oxygen saturation, or the other secondary end-
points signifi cantly differ between the two study periods. 
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We concluded that in children with CF who are on maintenance treatment with rhDNase 
it is equally effective and safe to nebulise rhDNase before bedtime or after waking up.  
In Chapter 5 we examined the nocturnal cough frequency in 25 children with stable CF. 
During two nights cough was recorded with a digital audio recorder. In addition, oxygen 
saturation was measured. The day following the recording spirometry was carried out. 
To quantify the severity of CF lung disease we scored the most recent routine CT scan. 
Cough was expressed in cough seconds and in cough seconds per hour.
We found that the frequency of nocturnal cough in these children was higher than that 
described for normal children. Nocturnal cough tended to be more severe in children 
with more advanced CF lung disease. Cough was more severe in the fi rst hour of sleep 
and was highly variable for individual patients from night to night. 
We concluded that more studies are needed to assess whether cough frequency is suf-
fi ciently sensitive to be used as a surrogate endpoint in clinical studies aimed to im-
prove mucociliary clearance. In addition, further studies should determine the optimal 
number of nights to be assessed for obtaining a reliable estimate of a patient’s severity 
of nocturnal cough. 
In Chapter 6 we examined oxygen saturation during sleep in 25 children with CF. During 
two nights oxygen saturation was measured using pulse oximetry. The days following 
the recordings, lung function tests were carried out. 
We found that the nocturnal oxygen saturation in children with stable CF was lower 
than that in healthy children, and was correlated with lung function parameters and CT 
scores. The mean oxygen saturation between the two nights correlated strongly. Lung 
function parameters did not predict nocturnal desaturation.
We concluded that monitoring oxygen saturation during one night is suffi cient to get a 
representative recording for an individual patient. 
In Chapter 7 we assessed the feasibility and sensitivity of a method to detect changes 
in airway resistance in relation to ACT. This interrupter technique (Rinte) was performed 
directly before and after ACT in 18 children with CF. The difference in Rinte was used as 
a measure of response to ACT. 
Sputum production was estimated with a semi quantitative scoring system. 
We found that Rinte was feasible in all children. Furthermore Rinte tended to improve 
after ACT and was negatively correlated to the sputum production. We concluded that 
Rinte is a feasible method but its clinical relevance for ACT in CF is questionable. 
In Chapter 8 we assessed whether we could improve CF patients’ knowledge about CF 
lung disease. As an instrument to teach children about CF lung disease we developed 
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a dedicated board game named ‘Airway’. Thirty-seven children aged 7-13 with CF were 
randomized into two groups. Both groups were tested twice with a written knowledge 
questionnaire that included questions about airways, CF and treatment. The children in 
the intervention group individually played ‘Airway’ with a pediatric physiotherapist with 
CF experience between the two questionnaire rounds. 
This study showed that the mean percentage of correct answers to the questionnaire 
increased in the intervention group but not in the control group. We concluded that 
playing the board game ‘Airway’ increased these children’s knowledge about CF lung 
disease.
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DISCUSSION AND RECOMMENDATIONS
This chapter discusses the relevance for clinical practice of particularly the timing stud-
ies. In addition recommendations for future research are given. 
10.1. Optimisation of timing of rhDNase inhalation
10.1.1. General discussion
The studies presented in this thesis focussed on an important knowledge gap concern-
ing CF lung disease. These were the fi rst studies to investigate the timing of the aerosol 
delivery of rhDNase in relation to ACT. Optimal timing is thought to be an important 
determinant for the effectiveness of this mucoactive drug.
Children who inhaled rhDNase before ACT showed improved peripheral airway patency. 
Furthermore, the impression that it is not safe to inhale rhDNase before sleep was not 
confi rmed. Clearly, at the time of the development of rhDNase an opportunity was 
missed to identify the optimal relation between inhalation of the drug and ACT. Like 
in other studies investigating the effectiveness of mucoactive drugs, it was left to the 
patients to decide on the order of aerosol delivery and ACT. From our results it would 
appear that the effectiveness of rhDNase could have been underestimated in the phase 
III studies. 
Hence, researchers investigating the effectiveness of mucoactive drugs or other inhaled 
drugs in CF should pay close attention to the optimal timing of inhalation in relation to 
ACT at an early stage of the drug development program. This is needed to optimise the 
costly, large-scale Phase III studies.  
10.1.2. Recommendations for clinical practice 
A practical implication of our fi ndings is the recommendation that patients should in-
hale rhDNase at the most convenient time of day, provided that they wait at least 30 
minutes before performing ACT. 
Physicians and physiotherapists should be aware that our studies focussed on children 
of 5 years and older. Nevertheless, in anticipation of the results of a study in younger 
children we advise that younger children, too, nebulise the rhDNase at least 30 minutes 
before ACT. 
10.1.3. Future research
Seeing that rhDNase is an established drug, it is striking that many avenues have been 
left unexplored that potentially can improve its effectiveness. The most important rec-
ommendation is to improve the effi ciency of aerosol delivery to especially the periph-
eral airways. Our observation that the patency of the peripheral airways could be im-
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proved, strongly suggests that the persistent peripheral airway obstruction is reversible 
– at least to some extent. Nebulisation of inhaled medications in CF such as rhDNase is 
commonly performed using highly ineffi cient nebulisers, resulting in poor deposition of 
the drug into the more peripheral airways. New smart nebulisers have been developed 
that are able to generate smaller particles with a limited size range that can be delivered 
more effi ciently to the peripheral airways. It is likely that the use of these smart nebulis-
ers will improve the effectiveness of rhDNase.1 We are awaiting the results of ongoing 
studies in our centre aimed to improve peripheral targeting of rhDNase.
The second recommendation is that we should investigate the effects of rhDNase in 
early disease. Our studies focussed on children of 5 years and older. Little is known, 
however, on the use of rhDNase in younger children. The main reason for this is the lack 
of robust endpoints in these young children. It has been shown that substantial irrevers-
ible structural damage can develop even in infants with CF.2 In only one randomized 
placebo controlled cross-over study in 9 infants it was shown that rhDNase improved 
the airway patency.3 Clearly, there is great need to further investigate the potential role 
of rhDNase in young children. An additional challenge is that ACT techniques for young 
children are poorly developed. 
The third recommendation is that patients with advanced to end stage lung disease 
should be studied more carefully. The CF population we investigated had relatively well 
preserved lung function. A recent study in patients who were transplanted for end stage 
lung disease showed that irreversible obstruction of peripheral airways plays a major 
role in the severe functional abnormalities in these patients.4 This suggests that patients 
with more advanced disease might benefi t from effective strategies to treat the periph-
eral airways. An option for patients with advanced disease who produce large amounts 
of sputum needs to be further studied: to perform ACT fi rst, next to nebulise rhDNase, 
and fi nally to repeat ACT. Obviously this strategy is very time consuming and therefore 
only advisable for patients with severe disease that progresses in spite of intensive 
treatment. 
Fourthly, in our CF centre the children are advised to intensively participate in sports 
as a method to increase their exercise tolerance and to mobilize sputum. The question 
whether it is more effi cacious to nebulise rhDNase before or after exercise has not yet 
been addressed. Clearly, this needs to be further investigated in a crossover randomized 
controlled study.
Ideally all our fi ndings should be further investigated in long term studies in larger 
cohorts, and with clinically relevant, sensitive endpoints. Running such studies with the 
current insensitive endpoints is extremely costly and would require a large number of 
patients. This would seem infeasible, therefore, as multicentre studies typically require 
up to 100 study sites. Yet, often no more than 5 patients per site can be included. Hence 
great effort should be made to develop clinically relevant, more sensitive endpoints. 
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10.2. ACT and Outcome measures
10.2.1. General discussion
The key surrogate endpoint in our studies was the MEF25. We chose this endpoint be-
cause it is considered to be more sensitive to changes in the small airways relative to 
FVC and FEV1.
5 It was no small feat being able to pick up a 6% difference in MEF25 be-
tween the two ACT-rhDNase regimens in a small cohort of patients, considering that 
they all were on maintenance rhDNase therapy. The importance of the MEF25 as a sur-
rogate endpoint in CF is undervalued. It can be derived from routine spirometry, which 
is a well-standardized technique. The use of MEF25 is especially relevant and feasible in 
studies addressing early lung disease in children aged 6 years and above.5
The importance of the other endpoints used - nocturnal cough, oxygen saturation and 
Rinte – is less obvious. 
Still, cough could be a feasible endpoint, as we found that it tended to be more severe 
in children with more advanced CF lung disease. Furthermore, cough is likely to be 
a clinically relevant endpoint since children cough more during pulmonary exacerba-
tions.6 
Likewise, our fi ndings point at oxygen saturation as a promising endpoint. Oxygen satu-
ration relates closely to the lung primary function as an organ for gas exchange. We 
found that a mean low saturation was associated with structural lung damage, as re-
fl ected by either a high total CT score or a high bronchiectasis subscore. Just like cough, 
oxygen saturation could be a clinically relevant endpoint too. All in all, one should be 
aware that sleep problems may have signifi cant effects on daytime functioning: even 
milder levels of desaturation have been associated with lower IQ and Attention Defi cit 
Hyperactivity Disorder symptoms.7 
The third endpoint that we evaluated was Rinte. Even though Rinte measurement was 
feasible in all eligible patients, its clinical relevance for ACT in CF is questionable. In our 
research ACT had only a borderline effect on Rinte. In addition, we found a signifi cant 
correlation with changes in Rinte with the reported amount of expectorated mucus, 
which cannot be considered a very sensitive and reproducible endpoint.  
10.2.2. Recommendations for clinical practice
Seeing the results of our study, we recommend physicians and physiotherapists to pay 
close attention to the MEF25 as a sensitive indicator of peripheral airways disease. Fur-
thermore, one should be alert to signs of desaturation, such as headache and tired-
ness, which are described to be associated with desaturation. Lung function parameters 
do not predict nocturnal desaturation events, unlike some other studies suggest. A 
nocturnal oxygen saturation measurement would be the assessment tool of choice to 
diagnose desaturation. 
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10.2.3. Future research 
Clearly, the search for new sensitive and accurate endpoints for ACT studies is a highly 
appropriate though relatively unexplored territory. Before nocturnal cough and oxygen 
saturation can be used as endpoints in children with CF to evaluate the effectiveness of 
(ACT) studies, more validation research is needed in the following areas.  
For cough it is important to determine its night-to-night variability and its response 
to changes in established treatments such as intravenous antibiotics. Furthermore the 
optimal number of nights needed to assess this variability should be established. In 
addition better software should be developed to improve analysis of the recordings. 
Currently, cough frequency analysis is too time consuming. Automated cough detection 
and analysis could well overcome this problem. To this end we have already started to 
develop such software in collaboration with a specialized centre. 
Similarly, further validation studies are needed for oxygen saturation. Its response to 
established treatments such as intravenous antibiotics needs to be further defi ned. In 
addition it needs to be determined what changes of oxygen desaturation are clinically 
relevant.8 Finally, it is evident that the relation between subnormal oxygen saturation 
profi les in CF on sleep quality, daytime functioning, IQ and behaviour should be further 
studied. The conclusions from such studies could be helpful in making decisions on 
when to start oxygen supplementation in CF.
Because Rinte measurement is one of the easiest ways to assess respiratory resistance 
during tidal breathing with minimal subject cooperation, this could be an excellent end-
point to use in infants. Further research in infants but also in adults is needed to further 
explore the potential of Rinte for ACT studies. 
There are other new developments that are of interest in the search for new sensitive 
and accurate endpoints: CT and Magnetic Resonance Imaging (MRI).  
CT has been shown to be more sensitive than pulmonary function tests to detect pro-
gression of CF lung disease. CT is the gold standard to detect bronchiectasis which 
is probably currently the most accurate and sensitive surrogate endpoint of CF lung 
disease. In addition, CT can detect and quantify trapped air, indicating small airways 
disease using ultra low radiation dose. 9 CT has now been used in several clinical studies 
and could play a role in future short and long term ACT studies. 
MRI has recently been used for ACT studies. Proton MRI enabled to visualise mucus and 
hyperpolarized 3-He MRI can detect ventilation defects. In a small interesting study 
(n=8) the researchers performed hyperpolarized 3-He MRI before and after ACT; they 
concluded that the total volume of ventilation defects had not changed.10 Further stud-
ies using proton and hyperpolarized 3-He MRI in larger groups of patients are needed 
to obtain more conclusive answers on the effect of ACT on mucus clearance. A major 
disadvantage of MRI is that the technique is expensive and relatively poorly standard-
ized. Yet it can be of great help to improve our understanding of the effects of ACT in CF.
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In conclusion, the currently used endpoints in ACT studies are not well developed. It is 
key that one should come up with more accurate, precise and easy to use endpoints for 
use in ACT studies.
10.3. Patient education and CF lung disease
10.3.1. General discussion
Since CF therapy is time consuming and complicated, we feel that it is important to 
teach young children about the basics of CF lung disease and the importance of therapy 
compliance. In addition they should learn to take (some) responsibility for their treat-
ment before they reach adolescence. Throughout adolescence children should move 
towards complete control over their lives. We showed that with the help of a purpose-
made board game, ‘Airway’, we could improve 7 to 12-year-old children’s knowledge 
about CF lung disease. It became clear from our study that a substantial number of 
children had important misapprehensions about their CF lung disease. 
10.3.2. Recommendations for clinical practice
It is worthwhile to incorporate the ‘Airway’ board game instrument into the regular 
teaching program for each child with CF. The game is played by a physiotherapist and 
a child with CF, in the hospital or at the home of the patient. It takes approximately 
45 minutes to play the game. Obviously the physiotherapist needs to have suffi cient 
knowledge about CF lung disease and its treatment. 
10.3.3. Future research
Clearly there are many unresolved questions related the use of the ‘Airway’ board game 
that need to be answered in future studies. Firstly, we do not know how long the children 
will hold on to the acquired knowledge. Hence, other studies are needed to establish 
the long-term effect of playing the ‘Airway’ board game on the children’s knowledge 
level. In addition we do not know whether better knowledge about CF lung disease truly 
results in better treatment compliance. 
In our study we administered a knowledge test to measure the increase of knowledge 
about CF lung disease after playing ‘Airway’. This test disclosed some important mis-
apprehensions, which we could then address on an individual basis. Once knowledge 
gaps have been uncovered, patients and parents can be taught individually. So, it would 
seem useful to construct a new questionnaire with (more) questions about the lung 
disease, treatment, medication, gastro-intestinal problems, etc. This questionnaire has 
to be adapted for various age ranges. Separate parent and child versions should also 
be available. 
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Continuous educational dialogue about the treatment is expected to stimulate the pa-
tient to take ownership for his treatment.11  
10.4. General conclusions 
This thesis presents several studies performed to optimize airway clearance in children 
with CF; focussing on timing, assessment and compliance related to ACT.
The fi rst part of this thesis shows better patency of the airways when rhDNase is nebu-
lised before the child performs ACT. We suggest that established drug therapies can 
be made more effective by optimizing the time relation between ACT and nebulisation 
of the drug. It is not unthinkable that alternative, even more effective regimens can be 
identifi ed in the future. Clearly when designing new studies the timing of medication 
and of other therapies like ACT must be taken into account. 
In the second part of this thesis alternative endpoints were explored. The currently 
used endpoints do not suffi ce for today’s pediatric CF population. There is a defi nite 
need for adequate surrogate endpoints that can be used in (ACT) studies. This thesis 
supports the use of peripheral airway fl ows. Nocturnal cough and saturation could well 
be feasible endpoints in children with CF, but more studies are needed to identify, for 
example, the sensitivity to treatment changes.
The last part of this thesis shows that the children’s knowledge of their CF lung disease 
can be improved by playing the board game ‘Airway’. This may have a positive effect on 
treatment compliance. One should be alert to children’s misapprehensions about their 
disease and its treatment. By designing a knowledge questionnaire, which can detect 
the gaps in their understanding, children can be educated individually in the future.
In conclusion, ACT forms an essential but time consuming part of CF treatment and 
therefore represents a great burden for most patients. It is in these children’s interest 
that we continue to optimise ACT. Currently used endpoints are inadequate for today’s 
pediatric CF population. Developing adequate surrogate endpoints is of prime impor-
tance in future research in patients with CF for further advancement of evidence based 
ACT practice.  
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SAMENVATTING
Cystic fi brosis (CF) is een autosomaal recessieve aandoening met een verkorte levens-
verwachting. Het is een chronisch, complex ziektebeeld waarbij verschillende organen, 
zoals longen, alvleesklier en lever zijn aangedaan. Chronische longinfectie en -ontste-
king beginnen al op de zuigelingenleeftijd en resulteren in verdikking van de luchtweg-
wand en verstopping van de kleine luchtwegen met purulente secreties. 
Het belangrijkste doel van de CF therapie op het gebied van de longen is om zo lang 
mogelijk een normale structuur van de longen te behouden en schade te voorkomen. 
De behandeling behelst regelmatig gebruik van anti-biotica, muco-actieve medicatie 
en airway clearance technieken (ACT). Behandeling duurt het gehele leven en vergt 
constante therapietrouw aan een complexe en tijdrovende therapie. Het is een enorme 
uitdaging voor de patiënt en het CF team om de therapietrouw zo groot mogelijk te 
laten zijn. 
Dit proefschrift richt zich op timing van rhDNase inhalatie en ACT, eindpunten voor 
wetenschappelijk onderzoek bij CF en op educatie aan kinderen met CF over de behan-
deling en kennis van de longen. 
Hoofdstuk 1 is een algemene introductie van dit proefschrift; Hoofdstuk 2 verklaart de 
opzet en het doel van de studies. 
In Hoofdstuk 3 wordt een gerandomiseerde, dubbel blind, dubbel dummy, cross-over 
studie beschreven, waarin bij 25 kinderen met CF het effect van inhalatie van rhDNase 
voor ACT is vergeleken met inhalatie van rhDNase na ACT. Alle kinderen gebruikten al 
langere tijd rhDNase. De kinderen werden verdeeld in twee groepen. Kinderen in de 
eerste groep inhaleerden rhDNase 30 minuten voor ACT, en een placebo direct na ACT 
in de weken 1-3. In de weken 4-6 werd het protocol omgedraaid. De andere groep volg-
de het protocol in precies de omgekeerde volgorde. Alle kinderen voerden dagelijkse 
ACT uit zoals zij gewend waren. Het primaire eindpunt was de MEF25 %pred, gebruikt als 
indicator van perifere luchtwegdoorgankelijkheid.  
Wij concludeerden dat door inhalatie van rhDNase voor ACT de MEF25 %pred verbeterde 
bij kinderen met CF. 
In Hoofdstuk 4 wordt de tweede gerandomiseerde, dubbel blind, dubbel dummy, 
cross-over studie gepresenteerd. Deze studie had tot doel om de effecten te vergelij-
ken als rhDNase voor het slapen gaan wordt geïnhaleerd ten opzichte van inhalatie na 
het wakker worden. Deze studie werd uitgevoerd bij 25 kinderen met CF. Alle kinderen 
gebruikten al langere tijd rhDNase. Ook hier werden de kinderen verdeeld in twee groe-
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pen. Kinderen in groep 1 inhaleerden rhDNase voor het slapen gaan, en een placebo na 
het opstaan gedurende week 1-2. Het protocol werd in de weken 3-4 omgedraaid. De 
andere groep volgde precies de andere volgorde gedurende de 4 weken. In de ochtend 
voerden de kinderen hun dagelijkse ACT 30 minuten na de inhalatie uit. Het primaire 
eindpunt was de MEF25 %pred, een indicator van de perifere luchtwegdoorgankelijkheid. 
Er werd geen signifi cant verschil in longfunctie parameters gevonden, als rhDNase voor 
het slapen gaan of in de ochtend werd geïnhaleerd. Tevens was er geen verschil in nach-
telijke zuurstofsaturatie, hoesten of de andere secundaire eindpunten. 
Vastgesteld kan worden dat bij kinderen met CF, die rhDNase als onderhoudsmedicatie 
hebben, het even effectief en veilig is om rhDNase voor het slapen gaan of in de och-
tend te inhaleren. 
In hoofdstuk 5 onderzochten we nachtelijk hoesten bij 25 kinderen met stabiel CF. Ge-
durende twee nachten werden de hoestgeluiden opgenomen met een digitale geluids-
recorder. Tevens werd tijdens deze nachten de zuurstofsaturatie gemeten. De dag na 
deze nachtelijke metingen werd longfunctie gemeten. Om de ernst van de longschade 
te kwantifi ceren werd de meest recente CT scan gebruikt. Hoesten werd uitgedrukt in 
hoestsecondes en in hoestsecondes per uur. 
We vonden dat de frequentie van het nachtelijk hoesten bij kinderen met CF hoger was 
dan welke beschreven is bij gezonde kinderen. Nachtelijk hoesten lijkt bij kinderen met 
meer longschade meer op te treden. Nachtelijke hoesten treedt in het eerste uur van 
de nacht meer op dan in de daaropvolgende uren en varieert sterk voor de individuele 
patiënt van nacht tot nacht. 
Concluderend zijn er meer studies nodig om te onderzoek of hoesten sensitief genoeg 
is om te worden gebruikt als eindpunt in CF studies, welke als doel hebben het effect 
van mucociliaire klaring te verbeteren. Tevens is meer onderzoek nodig om het optimale 
aantal metingen vast te stellen dat nodig is  om een betrouwbare schatting te verkrijgen 
van de ernst van het nachtelijk hoesten bij kinderen met CF. 
Hoofdstuk 6 beschrijft de studie waarin de nachtelijke zuurstofsaturatie bij 25 kinderen 
met CF gedurende twee nachten werd onderzocht. De zuurstofsaturatie werd gemeten 
middels pulse oximetrie. De dag na de nachtelijke metingen werd de longfunctie ge-
meten. Om de ernst van de longschade te kwantifi ceren werd de meest recente CT scan 
gebruikt.
Wij vonden dat nachtelijke zuurstofsaturatie bij kinderen met stabiel CF lager was dan 
beschreven bij gezonde kinderen. Er was een goede correlatie tussen de twee nachten 
wat betreft de zuurstofsaturatie. De nachtelijke zuurstofsaturatie was gecorreleerd met 
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longfunctie parameters en CT scores, maar de longfunctie kon geen voorspelling geven 
ten aanzien van nachtelijke desaturaties. 
Vastgesteld kan worden dat het monitoren van zuurstofsaturatie bij kinderen met CF 
gedurende één nacht genoeg is om een representatieve opname te krijgen. De long-
functie kan nachtelijke desaturaties niet voorspellen. 
In Hoofdstuk 7 wordt de toepasbaarheid en sensitiviteit van een methode om lucht-
wegweerstand middels de interruptie techniek (Rinte) te meten in relatie tot ACT be-
schreven. De Rinte werd direct voor en direct na ACT gemeten bij 18 kinderen met CF. 
Het verschil in Rinte werd gebruikt als eindpunt om het effect van ACT te meten. Sputum 
productie werd geschat met een semi-kwantitatief scoringssysteem. 
We vonden dat Rinte toepasbaar was bij alle kinderen. Rinte lijkt te verbeteren na ACT en 
was negatief gecorreleerd met de sputumproductie tijdens ACT. Concluderend is Rinte 
een toepasbare methode en kan mogelijk gaan dienen als eindpunt in kortdurende ACT 
studies.  
In Hoofdstuk 8 wordt de studie beschreven of de kennis over CF longziekte kon ver-
beteren bij kinderen met CF. Om deze kinderen meer te leren over CF longziekte is 
een bordspel ontwikkeld, genaamd ‘Vluchtweg’. Zevenendertig kinderen met CF in de 
leeftijd van 7-13 jaar werden verdeeld over twee groepen, een interventie en controle 
groep. Beide groepen kregen twee maal een kennistest met vragen over luchtwegen, 
CF en de behandeling daarvan. De kinderen in de interventiegroep speelden tussen de 
twee kennistesten het spel ‘Vluchtweg’ met een kinderfysiotherapeut, welke ervaring 
had met CF. 
De studie liet zien dat het gemiddelde percentage goede vragen op de kennistest toe-
nam bij de interventiegroep. 
Vastgesteld kan worden dat door het spelen van het spel ‘Vluchtweg’ de kennis van de 
kinderen over CF longziekte toenam. 
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DANKWOORD
Na 14000 kilometer met een 2CV, 27 koortslippen, 225 huisbezoeken, 3700 ampullen 
studiemedicatie en minstens 75 handtekeningen is mijn proefschrift klaar. 
Het is een zeer enerverende en uitdagende periode geweest. Naast mijn gewone werk 
in het Sophia Kinderziekenhuis als kinderfysiotherapeut heb ik gedurende 7 jaar de tijd 
gekregen om hieraan te werken. In deze tijd heb ik hulp van veel verschillende mensen 
gekregen. Een aantal van hen wil ik in het bijzonder dank zeggen:
Prof Dr HAWM Tiddens, beste Harm. Wat ooit begon als een oriënterende vraag in een 
restaurant in Orlando of ik ooit onderzoek wilde doen, is geresulteerd in dit proefschrift. 
Gedurende de gehele tijd van het onderzoek heb je mij weten te motiveren en ook 
geleerd om het einddoel voor ogen te houden. Er was maar een weg: ‘recht vooruit’. 
Tijdens het onderzoek heb je me ook menigmaal van vaderlijke adviezen voorzien. Maar 
Harm, wees gerust: mijn 2CV heeft een enorme kreukelzone en tijdens de winter heb-
ben wij op het schip net als iedereen gewoon de CV aan. Verder bewonder ik je om de 
vaart waarmee jij je leven leidt. De meeste mensen zouden hier meer levens voor nodig 
hebben. Ik vind het een eer om als eerste promovendus bij jou te promoveren. En als 
klapstuk van de dag speel jij met je band op het feest. Wat kan een promovendus zich 
nog meer wensen?
Prof R Gosselink, beste Rik. Ik wil je danken voor al je snelle adviezen en correcties die 
jij mij hebt gegeven tijdens deze periode. Het was zeer waardevol om naast kinderlong-
artsen ook vanuit het fysiotherapeutische vakgebied advies te kunnen krijgen. 
Prof Dr JC de Jongste, beste Johan. Bij aanvang van mijn studie was je mijn promotor. 
Het was voor jou geen probleem om deze plaats aan Harm af te staan. Ik denk dat dit 
jou kenmerkt. Jij geeft de mensen om je heen de ruimte die ze verdienen, om zo te kun-
nen groeien zonder dat je ze daar bij in de weg zou staan. Mijn grote complimenten. 
Verder veel dank voor al je snelle correcties en dat je bereid bent om in de kleine com-
missie plaats te nemen. 
Prof Dr AJ van der Heijden en Prof Dr HJ Stam wil ik bedanken voor de snelle beoorde-
ling van mijn proefschrift en de bereidheid om plaats te nemen in de kleine commissie. 
Prof dr K van der Ent, Dr M de Hoog en Dr VAM Gulmans wil ik bedanken voor het zitting 
nemen in de grote commissie.
Veel dank gaat uit naar alle kinderen die mee hebben gedaan aan het onderzoek. Vooral 
de rhDNase studies hebben veel van jullie gevraagd. Ik mocht bij jullie thuis komen 
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en zo ook een kijkje krijgen in jullie leven. Het is voor mij een heel bijzondere periode 
geweest waar ik met veel plezier aan terugdenk. Naast de kinderen die mee hebben 
gedaan aan het onderzoek wil ik alle kinderen met CF zeggen dat jullie enorm moedige 
en zeer bijzondere kinderen zijn. Ik ken weinig kinderen die met zo veel humor door het 
leven gaan. Het behandelen van jullie in de kliniek is nooit saai en vaak kan ik door jullie 
met een lach op mijn gezicht naar huis gaan. Ik hoop van ganser harte dat de weten-
schap nog veel grote stappen kan maken, zodat ook jullie een onbezorgde toekomst 
tegemoet kunnen gaan. Beste ouders, dank voor het vertrouwen dat ik jullie kinderen 
mocht en mag behandelen. 
Dr ir WCJ Hop, beste Wim. Aanvankelijk voelden mijn bezoeken bij jou alsof ik in een 
andere wereld belandde. Ik heb genoten van je verhalen over de tijd vóór SPSS en dat 
rokers de maatschappij alleen maar geld opleveren. Dank voor alle berekeningen en 
enthousiasme. En Wim, planten op een kamer hebben ook water nodig!
Beatrix Elink Schuurman, lieve Beatrix. Ik heb jou vaak de moeder van mijn onderzoek 
genoemd. In eerste instantie heb je me geholpen met het schrijven van het protocol 
volgens de ICH-GCP richtlijnen. Daarna kon je mij vervangen op de huisbezoeken. Het 
was echt super dat alles door kon gaan als ik een keer niet kon. Jij was het ook die al 
mijn SPSS fi les heeft gecontroleerd. Wat een monnikenwerk! Verder was het goed om 
af en toe even bij jou te kunnen binnenlopen als het even niet lekker liep. Helemaal fi jn 
was het toen ik een fout in de analyses ontdekte, dat je binnen een minuut naast me 
stond. Zo stond ik er nooit alleen voor. 
Ko Hagoort, of je nu in Rotterdam was of in een internetcafé in Bangkok, binnen een 
week gaf je antwoord. Door jouw correcties is dit proefschrift leesbaar geworden. 
Dit onderzoek was niet mogelijk geweest zonder fi nanciële steun van Roche Nederland 
BV. Ik wil Roche bedanken voor de mogelijkheid die zij boden om wetenschappelijk 
onderzoeksvragen en -studies in alle vrijheid uit te werken. Romedic wil ik danken voor 
het kosteloos te beschikking stellen van de vernevelaars. MMT wil ik danken voor het 
kosteloos uitlenen van de zuurstofsaturatiemeters. 
Naast mijn promotoren hebben ook andere mensen meegewerkt aan de artikelen en 
onderzoeken: 
Dr PJFM Merkus, Peter dank voor alle adviezen voor het Rinte artikel. 
Dr KFM Joosten, Koen, fi jn om naast het roeien ook op een andere manier met je ge-
werkt te hebben. 
Drs M Loeve, Martine, zonder jouw scherpe ogen waren de CT scores er niet geweest. 
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Drs EM Bakker, Marije, fi jn dat jij de eerste aanzet maakte van het saturatie artikel en je 
scherpe blik in mijn syntax fi les. 
Dr JBJ Bussmann, beste Hans, helaas heeft onze samenwerking niet tot een werkende 
cough sensor geleid, maar ook deze stappen horen bij het komen tot een nog beter 
product.
Dr H Escher, Hankje dank voor de suggesties over het ‘Vluchtweg’ artikel. Met jouw  ken-
nis over therapietrouw is het het alleen maar nog beter geworden.
Sandra Oude Sogtoen, Sandra dank voor al je bezoeken aan de kinderen. Jij was die-
gene die bij de kinderen het spel ‘Vluchtweg’ hebt gespeeld. Je hebt me heel veel werk 
uit handen genomen en met nog een geweldig resultaat ook!
De medewerkers van de ziekenhuisapotheek zorgden altijd weer dat weer dat alle am-
pullen op tijd klaar stonden. 
Dr S McKenzie, Dear Sheila, from the beginning you have been involved in my thesis. 
You were always willing to answer my questions and to advise me. Also many thanks for 
accompanying me to the symposium in Prague and helping me to prepare the article 
afterwards.
Eric Benda, hoofd van de afdeling Fysiotherapie, dank dat je mij in de gelegenheid 
stelde om op jouw afdeling aan mijn proefschrift te kunnen werken en dank voor je 
vertrouwen dat het tot een goed einde zou komen. 
Werk moet wat betreft inhoud inspirerend zijn, maar als je geen fi jne collega’s hebt, is 
werken eerder een last dan een lust. Gelukkig heb ik geweldige collega’s.
Annelies, dank voor al je inzet en geduld om mij goed Engels te laten spreken en voor je 
adviezen ten aanzien van Engelse zinnen in mijn artikelen. Jij liep voorop in het uitvoe-
ren van onderzoek. Dank voor datgene wat je me onderweg geleerd hebt. 
Annet, dank voor je gezelligheid en hulp in onze zware tijden. 
Carolijne, jonge hond, bijzonder dat je je vakantie voor mij verzet hebt ;)!
Esther, het is geweldig om te zien dat je de zorg voor de pasgeborenen zoveel nieuwe 
input hebt kunnen geven. Ook mijn benadering voor zuigelingen is er anders door 
geworden.
Kees, dank voor al de kopieën die je voor me hebt gemaakt. Heerlijk dat je bij ons werkt 
en de weg in het ziekenhuis zo goed kent, zodat er altijd wel weer een oplossing is.
Kim, net nieuw en het lijkt alsof je hier al jaren werkt. Het is een aanwinst dat je bij ons 
bent komen werken. 
Leontien, jonge hond, jouw enthousiasme en gezelligheid vervelen nooit.
Manon, weinig mensen kunnen zich zo wegcijferen als jij. Je hebt altijd oog en oor voor 
de ander. Ik hoop zo, dat je je weer vrij kunt gaan bewegen.
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Monique, grote bewondering heb ik voor je inzet waarmee jij je promotieonderzoek 
doet. Ik zie je groeien en blij worden van het onderzoek. En Monique, het leukste moet 
nog komen.
Nelleke, onze kruisende levens geven een band: basisschool, middelbare school, Thim 
van der Laan en het Sophia. Ik bewonder je moed om na een moeilijke periode weer als 
herboren aan het werk te zijn.
Netty, erg knap hoe jij je hebt weten te profi leren en met je eigen specialisme een plaats 
hebt weten te geven binnen de vakgroep kinderen. Dank voor al je belangstelling en je 
warme woorden.
Sandra, elke dag vanuit Brabant op en neer en nooit een klacht. Mijn complimenten hoe 
je de zorg voor de pasgeborenen op de kaart aan het zetten bent. Ik kan nog veel van 
je leren.
Suzan, jij was het die mij vertrouwen in mezelf gaf door kaartjes en lieve woorden. Het 
heeft heel veel voor mij betekend. Het is fi jn om meer dan een collega te zijn. En na-
tuurlijk heel veel dank dat je mijn proefschrift op punten en komma’s hebt nagelopen. 
Wilma, Dopje, steun en toeverlaat. Dank voor al je hulp, je geweldige verhalen, je gezel-
ligheid en je culinaire adviezen.
Het grote voordeel van lang bezig zijn met onderzoek is dat je veel onderzoekers leert 
kennen. Marije Bakker, Ruben Boogaard, Jeroen Hol, Carmelo Gabriele, Karen  Corver, 
José Esposito-Festen, Pim de Jong, Daan Caudri, Sonja Phaff, Dorien Wilschut, Annemie 
Boehmer, Eveline Nieuwhof, Els van der Wiel, Hettie Janssens, Mariëlle Pijnenburg, dank 
voor het brainstormen tijdens de researchbesprekingen, de gezelligheid en de steun 
tijdens congressen. In het bijzonder wil ik Ruben en Marije danken voor het pakje met 
tissues en chocolade. En inderdaad: “Hij die geen fouten maakt, maakt over het alge-
meen niets”.
De grote kracht van het CF-team is het grote scala van discipines. Annelies, Inge, Marit, 
Sylvia, Harm, Johan, Mariëlle, Hettie, Iris, Noor, Marjon, Baukje, Jessie, Hankje, Lissy, Yo-
lande, Heleen, Anke, dank jullie wel om zo ongedwongen met elkaar te kunnen werken 
en nog steeds te kunnen gaan voor verbetering van de zorg voor het kind met CF en 
zijn ouders. Speciale dank krijgt natuurlijk Irma Stok. Altijd ben je bereid om te helpen 
of mee te denken voor een oplossing. En helemaal fi jn om altijd weer op de hoogte te 
zijn van spannende of ontroerende boeken.
Gelukkkig mocht ik tijdens het onderzoek ook leren longfunctie bij kinderen te meten. 
Edith, Sabina en Sandra dank voor jullie instructies en hulp. 
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Lieve Alice en Danielle, paranimfen. Wat ben ik trots om jullie naast me te hebben. 
Alice, wij hebben samen wat af geabsorbeerd. Van samen koffi e drinken in de woonfl at 
in Leiderdorp tot duiken in Israël, van samen lopen door Cambridge tot rijden langs de 
Highway 1. Je bent een van de meest energieke, intelligentste, liefste en stimulerendste 
personen die ik ken. Het is een eer om je vriendin te mogen zijn. Danielle, het begon 
ooit dat ik je mocht inwerken, omdat je meeging als vrijwilliger op FOK-kamp. Daarna 
hebben we vele jaren samengewerkt. In jou vond ik een echte sparring partner. En wie 
wil er nou niet zijn presentatie oefenen in bikini op het strand van Kreta? Daan, heel 
knap dat je hebt gekozen voor een nieuw leven in het hoge Noorden. Super dat je naast 
me staat en ik hoop dat de afstand tussen ons overbrugbaar blijft. 
Tijdens het onderzoek ben ik in het ziekenhuis geholpen door een heleboel mensen. In 
de tussentijd moest het thuisfront ook doorgaan. Speciale dank ben ik verschuldigd aan 
Nicole van Genderen. Het was voor mij zo goed te weten dat Koen altijd bij jou terecht 
kon. Fijn dat je er die tijd voor hem was. Ook mijn lieve schoonouders Joke en Dick Onck 
hebben er menig weekje voor gezorgd dat ik naar een congres kon en dat Koen bij hen 
kon logeren of kwamen zelfs bij ons in huis. Dank jullie wel. 
Lieve vrienden en vriendinnen, het heeft inderdaad even geduurd. Elke keer dacht ik 
weer dat ik het komende jaar wel zou gaan promoveren. Maar nu is het er echt van ge-
komen. Dank voor al jullie gezelligheid, aandacht en liefde. 
Lieve papa, tijdens mijn onderzoekswerk overleed je; mijn vitale en sterke vader. Je werd 
zomaar ziek en binnen drie weken was je al overleden. Je hebt me duidelijk verteld dat 
je een goed leven hebt gehad en dat je met een gerust hart kon overlijden. Deze rust 
die jij had, heeft gezorgd dat ik niet anders kon dan te aanvaarden dat je er niet meer 
bent. Ik weet dat je enorm trots op me bent geweest, maar toch vind ik het verdrietig 
dat je niet bij de promotie kan zijn. En wat had ik je graag laten delen in ons leven op 
het schip!
Lieve mama, hoe twee mensen in elkaar verweven zijn, merk je soms pas als een van 
de twee er niet meer is. Ik weet dat je papa enorm mist, maar ben ook trots op je zelf-
standigheid. Dank voor al je zorg en aandacht. En fi etsen, dat blijven we gewoon doen!
Lisette, zomaar, 17 jaar geleden ben je verdwenen. De ergste nachtmerrie is voor je 
ouders, zus en broer toen werkelijkheid geworden. Voor mij was je mijn verlengstuk. 
We voelden elkaar feilloos aan en konden uren praten. Ik weet bijna zeker dat als je er 
nog zou zijn, dat ook jij was gaan promoveren. Ik mis je nog zo vaak. Voor je ouders, 
Lies en Gerrit heb ik een uitzonderlijke bewondering. Zij hebben de kracht gehad om 
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vanuit hun verdriet zoveel positieve energie te halen. Hiermee worden nu vele kinderen 
in India geholpen. 
Lieve Koen, toen ik met het onderzoek begon was je vier jaar. Toen ging je trots naar 
school om te leren schrijven met een pen. Inmiddels ben je 11 jaar. Je hebt je ontpopt 
als een stoere zeiler, een kanjer met wrikken, een natuurkenner, een zelfstandige jongen, 
een goede kok, een fi losofi sch kind etc. Met andere woorden, ik ben enorm trots op je. 
Soms heb je mij vergezeld op mijn huisbezoeken. Wat een gezelligheid was dat in de 
auto. Enige tijd geleden heb ik je verteld dat ik ging promoveren. Het enige antwoord 
wat dat ontlokte was: Ja, en dan? Zulke antwoorden zetten je weer even met beide be-
nen op de grond. Gelukkig was je laatst wel trots toen je zag dat ik alles in het Engels 
had geschreven. Koen, ik hoop dat het nog jaren zo gezellig blijft met jou aan boord. 
Dat je mag opgroeien tot een goed mens met oog voor de ander en de natuur. 
Allerliefste Jeroen, mijn kanjer. Tweeëntwintig jaar geleden zaten we samen voor het 
eerst in een klein bootje. Twaalf jaar geleden zijn we samen in het offi ciële bootje ge-
stapt en sinds 2008 wonen we samen op ons prachtige schip de Rien Sans Dieu. Wat 
ben ik trots op ons dat we “het gewoon gedaan hebben”! Samen met jou kan het leven 
geen sleur worden. Lieve Jeroen, met jou wil ik oud worden. Laat die stormen maar 
komen, die kunnen we aan!
En als laatste wil ik iedereen bedanken die naast mijn dankwoord en stellingen ook 
andere stukken uit dit proefschrift leest.
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CURRICULUM VITAE
Lianne van der Giessen werd geboren op 3 januari 1967 in Dordrecht. Zij groeide op in 
Dubbeldam. In 1985 legde zij met succes het VWO examen af aan het Christelijk Lyceum 
te Dordrecht. In datzelfde jaar begon zij met de studie fysiotherapie aan de Interna-
tionale Academie voor Fysiotherapie Thim van der Laan te Utrecht. Als student was zij 
actief in het begeleiden van mensen met een verstandelijke of lichamelijke beperking 
bij de Stichting Watersport met Gehandicapten in Loosdrecht. 
Na het behalen van haar diploma fysiotherapie in 1989 begon zij als fysiotherapeut in 
Nieuw Buitenzorg, een zorginstelling voor ernstig meervoudig beperkte kinderen in 
Leiderdorp. In 1990 begon zij met de postacademiale opleiding kinderfysiotherapie in 
Utrecht. Voor deze opleiding heeft zij onder andere stage gelopen in het Sophia Kinder-
ziekenhuis in Rotterdam, alwaar zij in oktober 1993 een vaste aanstelling kreeg. 
Sinds 1998 is zij bestuurslid van de Lisette Vroege Stichting. Deze stichting is opgericht 
ter nagedachtenis aan Lisette Vroege, een hartsvriendin van Lianne die sinds 1992 is 
vermist en wordt gemist. De stichting ondersteunt beperkte en kansarme kinderen in 
ontwikkelingslanden, die kinderfysiotherapeutische hulp nodig hebben.
Naast haar werk in het Sophia Kinderziekenhuis is zij betrokken bij de Masteropleiding 
Kinderfysiotherapie van de Transfergroep Rotterdam waar zij met name verantwoorde-
lijk is voor het blok onderzoek en behandeling bij kinderen met een pulmonale aan-
doening. 
Van 2000-2007 is zij eerst lid en later voorzitter geweest van de congrescommissie van 
de Nederlandse Vereniging voor Kinderfysiotherapie. 
In 2002 is zij in deeltijd gestart met haar onderzoek onder supervisie van Prof Dr HAWM 
Tiddens. Dit onderzoek wordt in dit proefschrift gepresenteerd. 
Lianne is getrouwd met Jeroen Onck. Zij hebben samen een zoon, Koen (1998). Zij 
wonen sinds 2008 in historisch Delfshaven op de Rien Sans Dieu, een Hasselteraak uit 
1907.  
Lianne BW.indd   153 10-07-09   11:13
Lianne BW.indd   154 10-07-09   11:13
List of publications
Lianne BW.indd   155 10-07-09   11:13
Lianne BW.indd   156 10-07-09   11:13
List of publications 157
LIST OF PUBLICATIONS
• Giessen LJ van der, Hartman A, Bouman NH. Somatoforme aandoeningen bij kin-
deren: indicatie kinderfysiotherapie? Tijdschr NVFK 1997;17:12-16.
• Giessen LJ van der, Liekens D, Rutgers KJM, Hartman A, Mulder PGH, Oranje AP. Vali-
dation of Beighton Score and Prevalence of connective tissue signs in 773 Dutch 
children. J Rheumatol 2001;28:2726-30.
• Jacobs-van der Bruggen M, Baan C, Hendriks E, Giessen LJ van der. Verslag pilot-
onderzoek “Fysiotherapie bij kinderen met astma”. Tjidschr NVFK 2000;1:10-12.
• Ketelaar M, Schie P van, Gorter JW, Visser J, Veenhof C, Voet F, Giessen LJ van der. Ac-
tuele ontwikkelingen in de Gross Motor Function Measure (GMFM). Kinderfysiothera-
pie 2003;15: 5-7.
• Giessen LJ van der, Pelt C van. Pas op, besmettingsgevaar! Kinderfysiotherapie 2003; 
15: 14-15.
• Giessen LJ van der, Theunissen C. Protocollering van het klinisch fysiotherapeutisch 
onderzoek bij patiënten met Cystic Fibrosis. Kinderfysiotherapie 2005; 17: 3-7.
• Giessen LJ van der, Gulmans VAM, Lucas T, Lugt M van der, Hendriks HJM. KNGF Richt-
lijn Astma bij kinderen. Ned Tijdsch Fys 2005;115(5). Supplement 
• Giessen LJ van der. In de beperking toont zich de meester. Kinderfysiotherapeutische 
behandelmogelijkheden van lage luchtweginfecties bij kinderen met een ernstig 
meervoudige beperking. TAVG 2007;25(3): 64-67. 
• Giessen LJ van der, Gosselink R, Jongste JC de, Hop WCJ, Tiddens HAWM. RhDNase 
before airway clearance therapy improves airway patency in children with CF. Pediatr 
Pulmonol. 2007 Jul;42(7):624-30. 
• Giessen LJ van der, Gosselink R, Jongste JC de, Hop WCJ, Tiddens HAWM. Recombi-
nant human DNase nebulisation in children with cystic fi brosis: before bedtime or 
after waking up? Eur Respir J. 2007 Oct;30(4):763-8. 
• Giessen LJ van der. Does the timing of inhaled dornase alfa matter? J Cystic fi brosis. 
2009;8: S6-S9.
Chapters in books
• Giessen LJ van der, Takken T, Vulmans VAM. Kinderfysiotherapie bij cardiopulmonale 
problemen. In: Empelen R, Nijhuis-van der Sanden R, Hartman A.(red) Kinderfysio-
therapie. Door: Elsevier Gezondheidszorg Maarsen. 2000.
• Giessen LJ van der, Gulmans VAM, Laag J van der. Fysiotherapie. In: Brand PLP, Hoek-
stra MO, Merkus PJFM, Schite PPM. Werkboek Kinderlongziekten. VU Uitgeverij. Am-
sterdam. 2001.
Lianne BW.indd   157 10-07-09   11:13
158 List of publications
• Giesen LJ van der. Fysiotherapie bij ademhalingsproblematiek. In: Kock- van Beer-
endonk I, Ridder I den, Westmaas A. Specialistische kinderverpleegkunde. Elsevier 
gezondheidszorg, Maarsen. 2006.
• Giessen LJ van der, Custers J, Douma D. Kinderfysiotherapie bij cardiopulmonale prob-
lemen. In: Empelen R, Nijhuis-van der Sanden R, Hartman A.(red) Kinderfysiotherapie. 
Door: Elsevier Gezondheidszorg Maarsen. Tweede druk, 2006. 
Lianne BW.indd   158 10-07-09   11:13
List of publications 159
ABBREVIATIONS
ACBT  Active cycle breathing techniques 
ACT  Airway clearance therapy 
AFRT  Artifact free recording time
ASE  ACT related sputum expectoration score
CF  Cystic fi brosis
CFQ  Cystic Fibrosis Questionnaire 
CFTR  Cystic fi brosis transmembrane regulator
CFRD  Cystic fi brosis related diabetes 
Cs/h  Cough seconds per hour
CSS  Cough symptom score 
D4  Fall in SO2 by ≥4% 
D90  Fall in SO2 to ≤90% 
DSE  Daily sputum expectoration score
FEV1   Forced expiratory volume in one second 
FEF75  Maximal expiratory fl ow when 75% of FVC is expired 
FVC  Forced vital capacity 
IQR  Inter quartile range
HRCT  High resolution computed tomography 
KQ  Knowledge questionnaire
MEF25  Expiratory fl ow at 25% of the actual forced vital capacity 
MCC  Mucociliairy clearance  
MRI  Magnetic resonance imaging 
ODI4  Oxygenation desaturation index per hour of D4
ODI90  Oxygenation desaturation index per hour of D90
PCL  Periciliary liquid
PFT  Pulmonary function test
Qol  Quality of Life
Rint  Interrupter resistance 
rhDNase  Recombinant human deoxyribonuclease 
SO2  Oxygen saturation
T4  Total time in seconds of D4
T90  Total time in seconds of D90
TOBI  Tobramycin solution for inhalation
TRT  Total recording time
TSI  Tobramycin solution for inhalation
sGaw  Specifi c airway conductance  
VAS  Visual analogue scale 
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